| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2023―Dec―03 |
193P Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab |
Y.B. Sang, C.R. Lee, S-G. Kim, B. Lee, C. Kim, H.J. Chon |
| 2 |
[GO] |
2023―Nov―14 |
MO51-2 Impact of COVID-19 on cancer care in India: A multi-institutional experience |
Manoj Kumar Behera, Dillip Agarawalla, Samrat Dutta, Kailash Mittal, Samir Kumar Mohanta, Manas Baisakh, Devikalyan Mishra |
| 3 |
[GO] |
2023―Nov―14 |
MO54-5 Assessment of the impact of COVID-19 on malignancy surgeries by interrupted time series analysis using real world data |
Mariko Nio, Tetsuro Oda, Yasuo Sugitani |
| 4 |
[GO] |
2023―Nov―14 |
MO54-4 The impact and development of the shared decision-making in cancer treatment during the COVID-19 pandemic |
Wan-Shiuan Lin, Yuan-Hao Yang |
| 5 |
[GO] |
2023―Nov―14 |
MO51-6 Impact of COVID-19 pandemic on the diagnosis of cancers - a systematic review |
Cheung Ka Tik |
| 6 |
[GO] |
2023―Oct―20 |
846P Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19 |
S. Assaad, J-Y. Blay, H. Crochet, P-E. Heudel, S. Bouam, M-P. Revel, G. Chassagnon, C. Bigenwald, L. Albiges, F. André, E. Battistella, O. Teboul, D. Pescia, B. Bertrand, E. D'Amico-Gandia, W. Kandeil, M. Guillet, A. Remorino, D. Dellamonica, N. Paragios |
| 7 |
[GO] |
2023―Oct―20 |
1231P Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer |
Y. Jung, S. Park, J-M. Sun, M-J. Ahn, J.S. Ahn, S-H. Lee, H.A. Jung |
| 8 |
[GO] |
2023―Oct―20 |
2285P Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls |
P.M.D.R. Cruz, F. Dias, T. Dias, M.S. Pimenta, H. Sousa, R. Medeiros, J. Oliveira |
| 9 |
[GO] |
2023―Oct―20 |
CN55 The impact of psychosocial support on the overall health of cancer patients in the COVID-19 era |
G. Catania, M.E. Musio, G. Fassio, G. Corci, L. Lungarotti, M. Zanini, L. Sasso, A. Bagnasco |
| 10 |
[GO] |
2023―Oct―20 |
1594P End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands |
E. Slotman, H. Fransen, H.W.M. van Laarhoven, M.H. van den Beuken-van Everdingen, V. Tjan-Heijnen, A. Huijben, A. Jager, C. van Zuijlen, E. Kuip, Y. van der Linden, N. Raijmakers, S. Siesling |
| 11 |
[GO] |
2023―Oct―20 |
900P COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study |
A. Psyrri, M. Kyprianou, S. Cavalieri, M. Oliva Bernal, J. Rogado, C. Pena, L. Iglesias, N. Baste Rotllan, B. Castelo, G. Fountzilas, C. Martinez-Vila, M. Cucurull Salamero, S. Triaridis, I. Diaz de Corcuera Frutos, E. Unal, M.L.K. Chua, N.F. Saba, R. Mesia Nin, L.F.L. Licitra |
| 12 |
[GO] |
2023―Oct―20 |
1986P Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry |
A. Mazzocca, S. Orlando, J. Aguilar Company, C.M. Valverde Morales, R.M. Bertulli, P. Sandwall, A.R. Sita-Lumsden, A. Bertuzzi, S. Rossi, A.J.X. Lee, C. Murphy, U. Mukherjee, F.A. Pommeret, G. Dettorre, C.A.M. Fulgenzi, A. Gennari, A. Napolitano, B. Vincenzi, D.J. Pinato, A. Cortellini |
| 13 |
[GO] |
2023―Oct―20 |
699P Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study |
E. Vita, F. Monaca, L. Mastrantoni, G. Piro, G. Moretti, I. Sparagna, A. Stefani, A. Vitale, G. Trovato, M. Di Salvatore, M. Sanguinetti, A. Urbani, L. Richeldi, C. Carbone, E. Bria, G. Tortora |
| 14 |
[GO] |
2023―Oct―20 |
1857P Psychological distress in Georgian cancer patients undergoing chemotherapy: Before and after the COVID-19 pandemic |
M. Abuladze, K. Saganelidze, T. Melkadze, E. Mariamidze, N. Otkhozoria, S. Tsitsilashvili, M. Katcharava, E. Kekelia, B. Tchatchiashvili, I. Kipiani, T. Esakia |
| 15 |
[GO] |
2023―Oct―20 |
1691O Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre in a public healthcare system |
C.C. Barron, T. Pittman, W. Xu, M. Madunic, J. Brierley, M.K. Krzyzanowska |
| 16 |
[GO] |
2023―Oct―20 |
648P Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study |
A. Parisi, F. Gelsomino, D. Traisci, F. Barbin, L. Salvatore, F.R. di Pietro, F. Zoratto, A. Lanese, A. Magnarini, A. Spallanzani, N. D'Ostilio, M. Bensi, F. Schietroma, R. Bisonni, M.B.L. Rocchi, R. Giampieri, G. Mentrasti, R. Berardi |
| 17 |
[GO] |
2023―Oct―20 |
899P Impact of COVID-19 pandemic on treatment and survival in head and neck squamous cell carcinoma (HNSCC) patients (IMPACCT Study) |
B. Vilar Anglada, P. Guillén Sentís, C. Castillo Manzano, J. Brenes Castro, F. Morey, S. Tous, B. Quirós, M. Plana Serrahima, A. Lozano, I. Linares Galiana, E. Vilajosana, C. Godino, M. Labori, M. Goma, A. Marí, O. Bermejo, M. Fulla, L. Alemany, M. Oliva |
| 18 |
[GO] |
2023―Oct―20 |
1432P Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry |
A. Thronicke, B.S. Matthes, C. Grah, P. Grabowski, F. Schad |
| 19 |
[GO] |
2023―Oct―20 |
1851P Psychological well-being of patients with colorectal cancer during the third wave of the COVID-19 pandemic: Results from cohort II of the PICO-SM study |
K.V. Kamposioras, K. Dadouli, P. Ntellas, K.H.J. Lim, M. Adamou, D. Anderson, L. Simpson, A. Shanthappa, M. Braun, J. Barriuso, J. Connell, J. Williams, D. Lehwald, J. Hasan, S. Mullamitha, K. Marti, M.P. Saunders |
| 20 |
[GO] |
2023―Oct―20 |
2286P COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer |
H.M.L. Le, A.M. Schmitt, S.T.C. Shepherd, A. Bhattacharya, C. Bresee, R.S.N. Fehrmann, S. Oosting, A.A.M. Van der Veldt, K. Reckamp, J.B.A.G. Haanen, E.G.E. de Vries, S. Turajlic |
| 21 |
[GO] |
2023―Oct―20 |
2166P Long-term consequences of SARS-CoV-2 infection in cancer patients |
Y. Debie, Z. Palte, H. Salman, L. Verbruggen, G. Vanhoutte, S. Raats, E. Roelant, T. Vandamme, M. Peeters, P.A. van Dam |
| 22 |
[GO] |
2023―Oct―20 |
463P Impact of two waves of Sars-Cov-2 outbreak on the clinical presentation and outcomes of newly referred breast cancer cases at AP-HP: A retrospective multicenter cohort study |
S. Priou, E. Guével, G. Lamé, J. Wassermann, R. Bey, C. Uzan, G. Chatellier, Y. Belkacémi, X. Tannier, S. Guillerm, R. Flicoteaux, J. Gligorov, A. Cohen, M-A. Benderra, L. Teixeira, C. Daniel, C. Tournigand, E. Kempf |
| 23 |
[GO] |
2023―Oct―20 |
1690O Impact of the SARS-CoV-2 outbreak on the initial clinical presentation of new solid cancer diagnoses: A systematic review and meta-analysis |
S. Marty, G. Lamé, E. Guével, S. Priou, G. Chatellier, C. Tournigand, E. Kempf |
| 24 |
[GO] |
2023―Oct―20 |
2287P Multiomic Biological mOdifications in the immune response of patients treated with chemotherapy, anti-CD20, or immune-checkpoint inhibitors and receiving a Third dose of vaccinE against SARS-CoV-2 (the BO0STER study) |
G. Zoppoli, L. Ferrando, F. Ravera, M. Dameri, I. Lombardo, M. Stabile, N. Fallani, B. Cigolini, G. Gentilcore, B. Bruzzone, A. Domnich, A. Orsi, F. Ballerini, D. Rinchai, D. Chaussabel, D. Bedognetti, J-C. Grivel, C. Genova, R. Lemoli, A. Ballestrero |
| 25 |
[GO] |
2023―Oct―20 |
2106P Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer |
A. Body, M.W. Donoghoe, E.S. Ahern, L. Lal, P. Downie, M.F. Leahy, N. Fuentes-Bolanos, A. Anazodo, B. Padhye, N. Hamad, C.E. Wakefield, E. Segelov |
| 26 |
[GO] |
2023―Jul―01 |
P-376 CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors |
R. Obermannová, I. Selingerova, R. Demlova, D. Valik, L. Zdražilová-Dubská, I. Kiss |
| 27 |
[GO] |
2023―Jul―01 |
P-313 Impact of COVID-19 on national trends of hospitalization and outcomes in pancreatic cancer patients presenting with venous thromboembolism in the United States |
L. Yadukumar, S. Chowdary, A. Sharma, N. Sharma |
| 28 |
[GO] |
2023―Jul―01 |
P-276 Robust and cost effective in-vivo CAM models for drug combination study in colorectal cancer during COVID-19 pandemic |
R. Aslam, S. Toomey |
| 29 |
[GO] |
2023―Jul―01 |
P-82 Impact of COVID-19 pandemic on metastatic colorectal cancer outcomes |
M. Pavlovic Mavic, P. Jaksic, P. Linaric, L. Vazdar, A. Tecic Vuger, R. Separovic |
| 30 |
[GO] |
2023―Jul―01 |
P-34 The changing risk of hospitalisation, intensive care admission and death due to COVID-19 in patients with gastrointestinal cancer in the UK |
M. Tilby, T. Starkey, M. Ionescu, L. Lee |
| 31 |
[GO] |
2022―Dec―04 |
428P Clinical characteristics, laboratory parameters, and hospital outcomes of COVID-19 among patients with and without cancer: A retrospective cohort study |
P. Sirohiya, H.K. Raju Sagiraju, M. Baruah, R. Singh, A. Elavarasi, S. Vig, B.K. Ratre, B. Kumar, A. Pandit, S. Bhatnagar |
| 32 |
[GO] |
2022―Dec―04 |
429P Cancer and COVID-19 in India: Assessing the impact in a nationwide survey |
B. Devnani, V. Noronha, B. Sirohi, K.D. Bambury, R.M. George, V. Pareek, G. Morgan |
| 33 |
[GO] |
2022―Dec―04 |
456P Outcomes of COVID-19 infection in cancer patients: A single center study |
S. Sindhu, A. Raghava K S, S.C. Bala, R. Chennamaneni, M.L. Konatam, S. Gundeti |
| 34 |
[GO] |
2022―Dec―04 |
286P Breakthrough COVID-19 infections in patients with cancer from a prospective study of COVID-19 vaccine response |
A. Body, E.S. Ahern, L. Lal, H. Abdulla, S. Opat, P. Downie, M. Leahy, N. Fuentes-Bolanos, B. Padhye, N. Hamad, V. Milch, E. Segelov |
| 35 |
[GO] |
2022―Dec―04 |
444P Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study |
E. Hirigoyen, N. Epaillard, M. Chastenet, R.A. Herve, J-P. Dutin, P. Gustin, L. Mahjoubi |
| 36 |
[GO] |
2022―Dec―04 |
244P Alternate-day hypofractionated radiotherapy for radical treatment of head & neck cancer during the COVID-19 pandemic: A single institute experience |
P. Singh, D.M. Joseph, A.S. Krishnan, R. Ahuja, S. Gupta, M. Gupta |
| 37 |
[GO] |
2022―Dec―04 |
457P The effect of Interleukin-6 (IL-6) on malignancy in COVID-19 patients in Dr. Moewardi General Hospital Surakarta |
M. Ardianti |
| 38 |
[GO] |
2022―Dec―04 |
453P Relationship between Interleukin-6 Levels (IL-6) and COVID-19 vaccination status in cancer patients at Dr. Moewardi General Hospital, Indonesia |
R.A. Hutabarat, W. Soewoto |
| 39 |
[GO] |
2022―Dec―04 |
426P Safety of Sputnik V COVID-19 vaccine in cancer patients receiving chemotherapy: An observational study |
A. Rumyantsev, E. Glazkova, M. Mariam, A. Darenskaya, H. Lud, A. Tryakin, A. Tyulyandina |
| 40 |
[GO] |
2022―Oct―07 |
Potentially Improved Response of COVID-19 vaccinated Nasopharyngeal Cancer Patients to Combination Therapy with Anti-PD-1 Blockade and Chemotherapy |
Y.J. Hua, Y.L. Liu, K. Wen, C. Kurts, H. Wu, Q. Mei, J. Li |
| 41 |
[GO] |
2022―Sep―16 |
T Cell Receptor Sequencing Reveals Reduced Clonal Breadth of T Cell Responses against SARS-CoV-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients |
A. Pradier, A.C. Mamez, C. Stephan, F. Giannotti, S. Masouridi-Levrat, S. Wang, S. Morin, D. Neofytos, D.L. Vu, A. Melotti, I. Arm, C.S. Eberhardt, J. Tamburini, L. Kaiser, Y. Chalandon, F. Simonetta |
| 42 |
[GO] |
2022―Sep―13 |
501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 |
S. Halabi, B. Luo, H. Dzimitrowicz, C. Hwang, T.M. Wise-Draper, C. Labaki, R.R. McKay, E. Ruiz, C. Rangel-Escareño, D. Farmakiotis, E.A. Griffiths, C.T. Jani, M. Accordino, C. Friese, E. Wulff-Burchfield, M. Puc, P. Yu, U. Topaloglu, S. Mishra, J. Warner |
| 43 |
[GO] |
2022―Sep―13 |
500P The impact of COVID-19 on the management and outcome of oncology patients: The results of the Middle East and North African (MENA) COVID-19 and Cancer Registry (MCCR) |
A.R. Jazieh, H. Abdel-Razeq, E.B. Köksoy, A. Bounedjar, A. Tafayli, E. Tashkandi, W. Jastaniah, J. Ansari, M.O. Alorabi, A.D. Darwish, A. Rabea, A.A.M. Alolayan, F. Ibnshamsa, H. Errihani, M. Alkaiyat, E. Garrett-Mayer, S.S. Bruinooge, F. Hussain, H. Tamim, K. AlKattan |
| 44 |
[GO] |
2022―Sep―13 |
174P Breast cancer (BC) and severe COVID-19 (C-19) outcomes: A matched analysis |
M. Chavez Mac Gregor, X. Lei, H. Zhao, C. Malinowski, S.H. Giordano |
| 45 |
[GO] |
2022―Sep―13 |
509P COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study |
O. Molinier, L. Falchero, I. Monnet, C. Decroisette, A-C. Neidhart, E. Redureau, A-M. Chiappa, F. Bigot, A. Bedossa, K. Amrane, S. Jeandeau, C. Dujon, A-S. Bugnet, P. Bonnefoy, C. Alizon, N. Meyer, S. Couraud, A. Cortot, A. Letierce, D. Debieuvre |
| 46 |
[GO] |
2022―Sep―13 |
502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer |
Z. Bakouny, P. Grover, C. Labaki, J. Awosika, S. Gulati, C-Y. Hsu, M.A. Bilen, O. Eton, L. Fecher, C. Hwang, H. Khan, R.R. McKay, E. Ruiz, L. Weissmann, M.A. Thompson, D. Shah, J. Warner, Y. Shyr, T.K. Choueiri, T. Wise-Draper |
| 47 |
[GO] |
2022―Sep―13 |
1615P The association of social distancing and obligatory face masks during COVID-19 era with the rates of febrile neutropenia in patients with solid tumors receiving antineoplastic therapy |
T. Shentzer Kutiel, A. Stern, M.T. Moskovits |
| 48 |
[GO] |
2022―Sep―13 |
1427P The role of anxiety and self-isolation in seropositivity for COVID-19 in actively treated cancer patients in Sweden |
B. Ginman, S. Pahnke, E. Freyhult, T. Hoffman, L. Kolstad, B. Rönnberg, Å. Lundkvist, K. Hamberg, G. Enblad, I. Glimelius |
| 49 |
[GO] |
2022―Sep―13 |
LBA70 COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases |
E. Romano, L. Castelo-Branco, Z. Tsourti, E. de Azambuja, S. Gennatas, J. Oliveira, J. Rogado, M. Sekacheva, S. Susnjar, D. Vinal Lozano, R. Lee, S.M. Khallaf, G. Dimopoulou, S. Pradervand, D. Arnold, K.J. Harrington, O.A. Michielin, U. Dafni, G. Pentheroudakis, S. Peters |
| 50 |
[GO] |
2022―Sep―13 |
510P Long-term outcomes of COVID-19 infection in patients with solid tumors before vaccination |
O. Yazici, O. Ünsal, Ö.F. Özkan, N. Ozdemir, G. Tahtaci, A. Uner, N. Günel, A. Özet |
| 51 |
[GO] |
2022―Sep―13 |
1366P Impact of COVID-19 on prostate cancer diagnosis and treatment |
R.L. Leszczynski, N. Norori, S. Beecroft, J. Wallace, B. Levick, M.D. Hobbs, T. Harding, G. Hall |
| 52 |
[GO] |
2022―Sep―13 |
505P The impact of COVID-19 on the wellness and resilience of the Canadian medical oncology workforce: A Canadian Association of Medical Oncologists survey |
L. Jones, B. Colwell, D. Hao, S. Welch, A. Campbell, S. Gill |
| 53 |
[GO] |
2022―Sep―13 |
1354P Delay of diagnoses, increase of advanced stages, and worse overall survival in patients with thoracic malignancies because of the COVID-19 pandemic |
A. Sbrana, S. Cappelli, I. Petrini, A. Chella, L. Carrozzi |
| 54 |
[GO] |
2022―Sep―13 |
1340P Trends in access to early phase clinical trials in underserved populations during the COVID-19 pandemic |
J. Balmaceda, D.P. Mudaranthakam, G. Doolittle, W. Sun, H. Krebill, T. Lin, A. Jewell, A. Saeed, S. Abbasi, R. Jensen, J.C. Baranda |
| 55 |
[GO] |
2022―Sep―13 |
1292P A review of in-hospital end-of-life care (EOLC) for oncology patients during the COVID-19 pandemic |
H.K. Carroll, A. Broderick, O. McCarthy, M. Kennedy, R. Bambury, D.G. Power, D.C. Collins, R.M. Connolly, S.A. Noonan, D. Collins, E. Cunningham, K. O'Driscoll, D. Nuzum, K. Twomey, A. O'Riordan, F. O'Sullivan, C. Roe, M.J. O'Leary, A.C. Lowney, S. O'Reilly |
| 56 |
[GO] |
2022―Sep―13 |
301P Hypofractionated radiotherapy for the treatment of newly diagnosed high-grade gliomas in younger and good performance status patients during COVID-19 pandemic |
A.C. Valente, C. Lopes Almeida, M.J. Costa, I.C. Nogueira Costa, J.S. Reis, M.C.B. Freitas, C.M. Teixeira, M.V. Gonçalves, A.C. Fernandes, A.S.A. Costa, C.L.B. Caeiro, L. Osório, I.M. Augusto, M. Barbosa |
| 57 |
[GO] |
2022―Sep―13 |
CN42 The impact of an education WhatsApp group to support nurses working in an acute oncology/haematology setting during the COVID-19 pandemic |
R.G. Lawless, C. O'Shea, R. Fox, A. Elliott, A. Smullen, N. Anderson |
| 58 |
[GO] |
2022―Sep―13 |
1515P Nationwide management of soft tissue sarcoma (STS) in France, before (2019) versus during COVID-19 pandemic (2020) |
N. Penel, A. Giraud, C. Chemin, C. Cantarel, F. Ducimetiere, C. Honoré, A. Le Cesne, F. Gouin, M. Toulmonde, G. Decanter, S. Bonvalot, C.M. Chevreau, P. Anract, N. Firmin, F. Duffaud, J.E. Kurtz, E. Bompas, M. Ropars, J-Y. Blay, S. Mathoulin-Pelissier |
| 59 |
[GO] |
2022―Sep―13 |
407P Cross-sectoral colorectal cancer care in Germany in the context of the COVID-19 pandemic and scarcity of resources |
C. Lugnier, T. Birkner, S. Sommerlatte, H. Hense, A-L. Kraeft, J. Christmann, S. Foerster, O. Schoffer, A. Stein, R. Reichelt, W. Knauf, O. Overheu, A. Tannapfel, J. Schildmann, A. Reinacher-Schick, J. Schmitt |
| 60 |
[GO] |
2022―Sep―13 |
1516P Diagnostic delay due to COVID-19 pandemic in sarcoma patients: Single-centre retrospective SarCorD study (COMETA Project) |
A. Cosimati, C.E. Onesti, S. Vari, F. Nardozza, G. Maggi, D. Minghelli, B. Rossi, F. Sperati, E. Checcucci, W. Faltyn, M.C. Cercato, F. Salvatori, F. Riva, R. Biagini, G. Ciliberto, V. Ferraresi |
| 61 |
[GO] |
2022―Sep―13 |
332P Impact of the COVID-19 pandemic in the early-onset colorectal cancer (EOCRC) |
I. Baraibar Argota, A. Garcia Rodriguez, F. Salvà Ballabrera, F.J. Ros Montana, N. Saoudi Gonzalez, R. Comas, G. Castillo, M. Sanchis, J. Hernando Cubero, A. García-Alvarez, J. Capdevila Castillon, M. Martí, S. Landolfi, E. Espin, P.G. Nuciforo, A. Vivancos, J. Tabernero, M.E. Elez Fernandez |
| 62 |
[GO] |
2022―Sep―13 |
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315) |
M. Sebastian, F. Griesinger, E. von der Heyde, S. Dörfel, J.H. Wiegand, C. Schiefer, C. Losem, M. Jänicke, A. Fleitz, S. Zacharias, A. Hipper, C. Dietel, A. Bleckmann, R. Benkelmann, M. Boesche, C. Grah, A. Müller, W.E.E. Eberhardt, M. Thomas |
| 63 |
[GO] |
2022―Sep―13 |
1344P Impact of COVID-19 pandemic on cancer care provision: A cross-sectional study of Egyptian patients’ perspectives and concerns |
A.M. Abdou, S. Khalil, M. Yassin, M.A.A. Amin, S. Alyamani, A.H. Abdelaziz |
| 64 |
[GO] |
2022―Sep―13 |
716P Impact of COVID-19 pandemic on clinical outcomes in hepatocellular carcinoma: A multicentre cohort study |
S. De Souza, J. Kahol de Jong, R. Jones, H. Reeves, S. Shetty, J. Orr, D. Bettinger, V. Yip, L. Temperley, D. Geh, M. Qurashi, B. Allen, L. Sturm, A. Banerjee, P. Ross, R. Sharma |
| 65 |
[GO] |
2022―Sep―13 |
CN35 Workplace violence against cancer nurses during the COVID-19 pandemic: A correlational-predictive study |
G. Catania, N. Pagnucci, R. Alvaro, G. Cicolini, A. Dal Molin, L. Lancia, M. Lusignani, D. Mecugni, P.C. Motta, R. Watson, M. Hayter, F. Napolitano, M. Zanini, L. Sasso, A. Bagnasco |
| 66 |
[GO] |
2022―Sep―13 |
CN26 Nurses caring for patients at the end of life report affected psychosocial work environment when relocated during the COVID-19 pandemic: A cross-sectional study |
C. Olsson, M. Dahlen Granrud, M. Tillfors, C. Bååth, V. Abrahamsen Grøndahl, A.K. Helgesen, I. Henoch, C. Melin-Johansson, J. Österlind, M. Larsson |
| 67 |
[GO] |
2022―Sep―13 |
1228P Stage migration, changed treatment profile and survival impact in newly diagnosed oesophago-gastric cancer in Scotland during the COVID-19 pandemic: A national study |
M. Baxter, K.S. Khan, L. Gall, C. Samuelson, L.R. Narramneni, M. Al-Zuabi, G. Bryce, H. Shareef, R. Petty, M. Forshaw |
| 68 |
[GO] |
2022―Sep―13 |
1629P Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network |
J.C. Benitez, J. Florez-Arango, M-E. Boucher, E. Dansin, M. Kerjouan, L. Bigay-Game, E. Pichon, F. Thillays, P-E. Falcoz, S. Lyubimova, Y. Oulkhouir, F. Calcagno, L. Thiberville, C. Clément-Duchêne, V. Westeel, P.A. Thomas, J-M. Maury, T. Molina, N. Girard, B. Besse |
| 69 |
[GO] |
2022―Sep―13 |
CN40 Nurses’ experiences during the COVID-19 pandemic: Multicenter mixed-methods study of coping and resilience strategies |
L. Cadorin, S. Cedrone, J. Polesel, C. Mazzega Fabbro |
| 70 |
[GO] |
2022―Sep―13 |
1610P Humoral immune response to COVID-19 vaccination in patients with cancer: The ANRS0001S COV-POPART study |
L.B. Luong Nguyen, M. Chalouni, P. Loubet, N. Dohollou, O. Tredan, M. Veyri, Z. Maakaroun-Vermesse, I. Ben Ghezala, E. Fourn, D. Merrien, C. Cracowski, A. Barquin, A. Levier, L. Wittkop, O. Launay, J-Y. Blay, J-P. Spano |
| 71 |
[GO] |
2022―Sep―13 |
1612P Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy |
D.C.C. Guven, F.G. Gulbahce Incesu, H.C. Yildirim, E. Erul, E. Chalabiyev, B.Y. Aktas, D. Yuce, Z. Arik, S. Kilickap, S. Aksoy, M. Erman, K.M. Hayran, S. Unal, A. Alp, O. Dizdar |
| 72 |
[GO] |
2022―Sep―13 |
1614P Influence of cancer on COVID-19 vaccine beliefs, attitudes and uptake |
M. Nguyen, N.T. Bain, L. Grech, A. Kwok, N. Hamad, A. Tognela, B.A. Chan, L.M. Nott, S. Harris, N.M.H. Chau, C.R. Underhill, D. Day, A. McCartney, K. Webber, E. Segelov |
| 73 |
[GO] |
2022―Sep―13 |
1609P Cannabis impacts on serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer |
A. Zer, T.G. Goshen-Lago, I. Ben-Aharon, M. Passhak |
| 74 |
[GO] |
2022―Sep―13 |
504P SARS-CoV-2 Omicron (B.1.1.529) variant infection leads to high morbidity and mortality in unvaccinated patients with cancer |
D.J. Pinato, J. Aguilar-Company, A. Bertuzzi, G.H. Hanbury, M.D. Bower, R. Salazar, M. Lambertini, P. Pedrazzoli, A.J.X. Lee, A. Sinclair, S. Townsend, A. Plaja Salarich, A.R. Sita-Lumsden, U. Mukherjee, N. Diamantis, R. Sharkey, G. Gaidano, A. Gennari, J. Tabernero, A. Cortellini |
| 75 |
[GO] |
2022―Sep―13 |
1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients |
Y. Debie, J. Van Audenaerde, T. Vandamme, L. Croes, L-A.M.N. Teuwen, L. Verbruggen, G. Vanhoutte, E. Marcq, D. Le Blon, B. Peeters, K. Arien, S. Anguille, E. Smits, C. Vulsteke, E. Lion, M. Peeters, P.A. van Dam |
| 76 |
[GO] |
2022―Sep―13 |
1430P Psychological status and patient perception during the SARS-CoV-2 vaccination campaign in active oncological patients (pts) |
T. Daniela, A. Avancini, L. Belluomini, I. Trestini, S. Zuliani, T. Sava, C. Gaiani, A. Caldart, M. Casali, L. Benini, F. Zacchi, E. Trevisani, F. Bianchi, S.T. Riva, A. Tfaily, M. Rimondini, G. Verlato, S. Pilotto, M. Milella |
| 77 |
[GO] |
2022―Sep―13 |
1611P Clinical determinants of SARS-CoV-2 vaccine response in adults with cancer |
E. Segelov, A. Body, L. Lal, H. Abdulla, S. Turville, Z. Naing, S. Opat, M. Leahy, J.R. Balendra, N. Hamad, R. Mccuaig, S. Rao, K. Lineburg, C. Smith, C.R. MacIntyre, V. Milch, L. Busija, E.S. Ahern |
| 78 |
[GO] |
2022―Sep―13 |
CN46 Catheter-related venous thrombosis: Experience with blue advance peripherally inserted central catheter (PICC) in a day hospital during the pandemic |
F. Losa, M. Mancha, N. Moragriega, A. Perez, A. Manzana, A. Rios, A. Aranda, E. Cabezudo |
| 79 |
[GO] |
2022―Sep―13 |
209P Efficacy and feasibility of long acting every three months goserelin for premenopausal breast cancer patients during COVID pandemic |
S.F. El Zawawy, G. Khedr |
| 80 |
[GO] |
2022―Sep―13 |
1333P S1 Guideline for prioritisation in gastrointestinal cancer care: Scarcity of resources in the pandemic context |
A. Reinacher-Schick, C. Lugnier, S. Sommerlatte, T. Birkner, O. Schoffer, A-L. Kraeft, S. Foerster, W. Knauf, B.O. Maier, E. Fokas, M. Ebert, P. Piso, K-S. Monika, J. Christmann, R.D. Hofheinz, A. Tannapfel, B.J. Woermann, J. Schmitt, J. Schildmann |
| 81 |
[GO] |
2022―Sep―13 |
41P Clinical characteristics and outcomes of COVID-19 in 1295 new cancer patients: Single-center, prospective cohort study from Iran |
S.A. Javadinia |
| 82 |
[GO] |
2022―Jul―21 |
MO22-1 Outcomes and Risk Factors of Patients with COVID-19 and Cancer (ONCORONA): A Sub-study of the Philippine CORONA study |
Ramon Jr B. Larrazabal, Adrian I. Espiritu, Marie Charmaine C. Sy, Veeda Michelle M. Anlacan, Roland Dominic G. Jamora |
| 83 |
[GO] |
2022―Jul―21 |
EJS-1 Flexibility to sustain solidity. Addressing new vulnerabilities in cancer at the time of COVID-19 |
Solange Peters |
| 84 |
[GO] |
2022―Jul―21 |
JS1-1 Impact of COVID-19 for cancer screening and cancer treatment in Japan |
Hirokazu Takahashi |
| 85 |
[GO] |
2022―Jul―21 |
MO22-2 Thromboembolic events associated to COVID-19 in a breast cancer cohort during the most recent waves of the disease |
Jorge Illarramendi, Juan Ignacio Arraras, Gema Asin, Ana Manterola, Katy Paola Zavala, Sonia Flamarique, Esteban Salgado, Susana De La Cruz, Jose Juan Illarramendi |
| 86 |
[GO] |
2022―Jul―21 |
MO22-3 Gravity of COVID-19 infection in oncology patients undergoing active treatment, a Romanian Cancer Center experience |
Ramona Matei |
| 87 |
[GO] |
2022―Jul―21 |
MO22-5 COVID-19 lockdown: Psychological impact on breast cancer patients |
Shekhar Goyal, Surender Kumar Beniwal, Rakesh Kumar, H.S. Kumar, Dhruv Kumar, Bhudev C. Das |
| 88 |
[GO] |
2022―Jul―21 |
JS1-5 Management of hematological disorders in COVID-19 pandemic |
Masao Hagihara |
| 89 |
[GO] |
2022―Jul―21 |
P55-2 An analysis of trends in tele-prescription of anticancer agents during the COVID-19 pandemic |
Masami Tsuchiya |
| 90 |
[GO] |
2022―Jul―21 |
P40-9 Continued report on the Cancer Salon at Jichi Medical University Hospital - Restart under the COVID-19 pandemic |
Rie Yamamoto, Kaori Komatsuzaki, Yoshiko Kojima, Miwako Inada, Yumi Ooeda, Masaaki Inoue, Saori Chiba, Akiko Nakayama, Kiyoe Sato, Hironori Yamaguchi |
| 91 |
[GO] |
2022―Jul―21 |
EJS-4 The impact of COVID-19 pandemic on the new drug development and exploration of new trial design |
Noboru Yamamoto |
| 92 |
[GO] |
2022―Jul―21 |
MO22-4 Impact of the COVID-19 pandemic on the treatment schedules of cancer patients receiving systemic treatment |
Aylmer Rex B. Hernandez, Alfredo Jr. V. Chua, Gracieux Y. Fernando |
| 93 |
[GO] |
2022―Jul―21 |
P21-1 The herbal treatment of COVID-19 proved to be boon for cancer patients a observational cross sectional study |
Jitendra Acharya |
| 94 |
[GO] |
2022―Jul―21 |
EJS-2 COVID-19 vaccination in cancer patients |
Emanuela Romano |
| 95 |
[GO] |
2022―Jul―21 |
EJS-3 How do we, as a society, respond to COVID-19? |
Norio Ohmagari |
| 96 |
[GO] |
2022―Jul―21 |
MO30-1 Factors critical for the acquisition of antibody after SARS-CoV-2 vaccination in malignant lymphoma patients |
Akinao Okamoto, Fujigaki Hidetsugu, Iriyama Chisako, Goto Naoe, Yamamoto Hideyuki, Mihara Keichiro, Inaguma Yoko, Miura Yasuo, Furukawa Katsuya, Yamamoto Yukiya, Akatsuka Yoshiki, Kasahara Senji, Miyao Kotaro, Masataka Okamoto, Kuniaki Saito, Akihiho Tomita |
| 97 |
[GO] |
2022―Jul―21 |
P72-5 Is rapid antigen detection test suitable as community screening for SARS-CoV-2? |
K.T. Cheung, Ellie S.M. Chu, Ricky W.K. Wu, C.K. Cheng, Ava Kong, Oliver Ma, Joseph S.K. Lee |
| 98 |
[GO] |
2022―Jul―21 |
P31-1 Psychosocial aspects in relation to ovarian cancer patients after COVID pandemic in South India - observational study |
Chandralekha Krishnan, Senthil Kumar Elumalai, Siva Subramaniam, Gangadharan Sgd |
| 99 |
[GO] |
2022―Jul―02 |
P-231 Impact of COVID-19 on colorectal cancer management: Single-center experience |
D. Silva, M. Vilaca, D. Magalhães, M. Costa, C. Sottomayor, M. Salgado, A. Mesquita |
| 100 |
[GO] |
2022―Jul―02 |
PD-1 The impact of COVID-19 on diagnosis, stage and treatment of esophageal and gastric cancer |
J. Bakx, B. Doeve, P. Siersema, C. Rosman, N. Grieken, M. van Berge Henegouwen, J. van Sandick, M. Verheij, M. Bijlsma, R. Verhoeven, H. van Laarhoven |
| 101 |
[GO] |
2022―Jul―02 |
P-149 Impact of COVID-19 pandemic and total neoadjuvant therapy (TNT) implementation in pathological complete response (pCR) rates in patients (pts) with locally advanced rectal cancer (LARC) |
D. Gómez-Puerto, L. Benini, J. Hernando, A. García Álvarez, S. Vega-Cano, G. Molina Lores, J. Yaringaño, D. López, C. Salva de Torres, J. Ucha Hermida, S. Bueno, B. Navalpotro, M. Roca, F. Vallrivera Valls, M. Martí Gallostra, M. Kraft, J. Sanchez Garcia, A. Solis, F. Marinello, J. Capdevila, E. Espín Basany |
| 102 |
[GO] |
2022―Jul―02 |
P-37 Has the COVID-19 pandemic lead to an upshift in emergency presentation and stage migration of colorectal cancer in Uruguay? |
S. Fontes, M. Berry, A. Marín-Jiménez, G. Krygier, M. Cuello |
| 103 |
[GO] |
2022―Jul―02 |
P-109 Care delivery impact of the COVID-19 pandemic on anal cancer care |
E. Saldanha, M. Powis, F. Cavalher, S. Hack, M. Simoes, M. Costa, A. Baiad, Z. Mohmand, K. Chen, P. Nakhla, O. Espin-Garcia, L. Huaqi, R. Riechelmann, M. Krzyzanowska |
| 104 |
[GO] |
2022―Jul―02 |
P-75 Digestive tumours in the elderly during COVID pandemic |
A. Benzazoua, S. Ghomari-Bezzar |
| 105 |
[GO] |
2022―Jun―18 |
25P The impact of COVID-19 on delaying diagnostic-therapeutic pathways of endometrial cancer patients: The Italian real-world scenario |
V. Di Donato, G. Scambia, P. Benedetti Panici, F. Raspagliesi, G. Bogani |
| 106 |
[GO] |
2022―Jun―18 |
38P Impact of 1-year COVID-19 pandemic in patients with ovarian carcinoma treated with chemotherapy based on a global data network |
L.M. Manso Sanchez, A. Madariaga Urrutia, G. Hernández-Ibarburu, R. Sanchez Bayona, P. Tolosa Ortega, L. Lema Roso, M. Alva, A. Modrego, P. Serrano, L. Paz-Ares |
| 107 |
[GO] |
2022―Jun―14 |
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study |
Z. Bakouny, C. Labaki, S. Bhalla, A.L. Schmidt, J.A. Steinharter, J. Cocco, D.A. Tremblay, M.M. Awad, A. Kessler, R.I. Haddad, M. Evans, F. Busser, M. Wotman, C.R. Curran, B.S. Zimmerman, G. Bouchard, T. Jun, P.V. Nuzzo, Q. Qin, L. Hirsch, J. Feld, K.M. Kelleher, D. Seidman, H. Huang, H.M. Anderson-Keightly, T. El Zarif, S. Abou Alaiwi, C. Champagne, T.D. Rosenbloom, P.S. Stewart, B.E. Johnson, Q. Trinh, S.M. Tolaney, M.D. Galsky, T.K. Choueiri, D.B. Doroshow |
| 108 |
[GO] |
2022―May―05 |
153P The role of screening in the timely diagnosis of breast cancer in the COVID-19 pandemic context |
D. Kaidarova, A. Zhylkaidarova, M.I. Saktaganov, Z. Dushimova, O. Shatkovskaya |
| 109 |
[GO] |
2022―May―05 |
240P COVID-19 pandemic impact on diagnosis and management of breast cancer in Northern Portugal |
R. Teixeira-Pinto, J. Rodrigues, P. Redondo, M. José-Bento, J. Savva-Bordalo |
| 110 |
[GO] |
2022―May―05 |
107P Impact of COVID-19 pandemic on breast cancer neoadjuvant therapy: A retrospective institutional analysis |
M.C. Baptista Freitas, C. Lopes de Almeida, A.C. Valente, M.J. Costa, I.C. Nogueira Costa, J.S. Reis, N.T. Tavares, I.J. Dionísio de Sousa, D.P.S. Almeida, C.L.B. Caeiro, I.M. Augusto, L.M. Nunes Aguas, M. Barbosa |
| 111 |
[GO] |
2022―May―05 |
210P Worsening of breast cancer patients’ condition: What happened during COVID-19? A meta-analysis |
M. Nagy, S.E. Abdel Mawgoud |
| 112 |
[GO] |
2022―May―05 |
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome? |
S.A. Javadinia, M. Dehghani, M. Ariamanesh, Z. Roudsarabi |
| 113 |
[GO] |
2022―May―05 |
229P Efficiency of SARS-CoV-2 vaccines in breast cancer patients: Single institutional experience from Institute for Oncology and Radiology of Serbia (IORS) |
O.I. Djurmez, M.D. Calamac, M. Dimitrijevic, J.G. Vukosavljevic, K. Serovic, J. Oblakovic-Babic, N.S. Stanic, I.Z. Minic, Z. Tomasevic, I. Bozovic Spasojevic |
| 114 |
[GO] |
2022―May―05 |
151P Personalized approach to mammography screening during the COVID pandemic: How to make up for lost time without losing effectiveness |
F. Giovanardi, G. Bisagni, E. Gasparini, A. Bologna, R. Di Cicilia, G. Moretti, C. Pinto |
| 115 |
[GO] |
2022―Apr―09 |
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study. |
F. Nelli, D. Giannarelli, A. Fabbri, M.A. Silvestri, J.R. Giron Berrios, A. Virtuoso, E. Marrucci, M. Schirripa, M. Mazzotta, A. Onorato, V. Panichi, G. Topini, G. Pessina, F. Natoni, C. Signorelli, M.G. Chilelli, F. Primi, E.M. Ruggeri |
| 116 |
[GO] |
2022―Apr―02 |
104P The potential for lung cancer detection in COVID-19 CT scans with AI technologies usage |
S.V. Zinovev |
| 117 |
[GO] |
2022―Apr―02 |
190P COVID-19 pandemic impact on lung cancer patient’s performance status and access to treatment: A comparative study pre and during COVID-19 era |
R. Fernandes, M. Pina, C. Fava Gaspar, A.R. Teixeira, C. Oliveira, A. Rodrigues, I. Azevedo |
| 118 |
[GO] |
2022―Apr―02 |
103P Effectiveness of artificial intelligence in retrospective COVID-19 lung CT analysis for lung cancer detection |
S. Pirgulov |
| 119 |
[GO] |
2022―Apr―02 |
191P Lung cancer care in Europe during COVID-19: Findings from a global survey of patient experience |
J. Fenemore |
| 120 |
[GO] |
2022―Apr―02 |
188P Efficacy of SARS-CoV-2 based mRNA vaccines for patients with thoracic malignancies with 6 months follow up: A prospective observational study |
U. Janzic, K. Mohorcic, L. Mrak, M. Ivanovic, U. Bidovec Stojkovic, J. Debeljak, P. Korosec, M. Rijavec |
| 121 |
[GO] |
2022―Apr―02 |
189P Assessment of seroconversion after SARS-CoV2 vaccination in patients with lung cancer |
I.P. Trontzas, I. Vathiotis, G. Gomatou, M. Grammoustianou, I. Tsamis, M. Anagnostakis, V. Sakka, G. Poulakou, K.N. Syrigos, E.A. Kotteas |
| 122 |
[GO] |
2022―Mar―09 |
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona. |
S. Zanelli, E. Fiorio, I. Zampiva, F. Zacchi, G. Borghesani, E. Giontella, V. Parolin, P. Biondani, S. Zuliani, M.V. Dieci, E. Mioranza, M. Zorzi, M. Conti, D. Gibellini, G. Verlato, M. Milella |
| 123 |
[GO] |
2022―Mar―08 |
41P The SARS-CoV-2 vaccine and enrollment of patients with cancer in phase I trials: The experience at Institute Gustave Roussy |
L. Belcaid, C. Baldini, A. Laparra |
| 124 |
[GO] |
2021―Dec―24 |
COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer |
A.L. Schmidt, C. Labaki, C.-Y. Hsu, Z. Bakouny, N. Balanchivadze, S.A. Berg, S. Blau, A. Daher, T. El Zarif, C.R. Friese, E.A. Griffiths, J.E. Hawley, B. Hayes-Lattin, V. Karivedu, T. Latif, B.H. Mavromatis, R.R. McKay, G. Nagaraj, R.H. Nguyen, O.A. Panagiotou, A.J. Portuguese, M. Puc, M. Santos Dutra, B.A. Schroeder, A. Thakkar, E.M. Wulff-Burchfield, S. Mishra, D. Farmakiotis, Yu Shyr, J.L. Warner, T.K. Choueiri |
| 125 |
[GO] |
2021―Dec―10 |
Six-months immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: Updated results of the Vax-On study |
F. Nelli, A. Fabbri, A. Onorato, D. Giannarelli, M.A. Silvestri, G. Pessina, J.R. Giron Berrios, A. Virtuoso, E. Marrucci, M. Schirripa, M. Mazzotta, V. Panichi, P. Cercola, C. Signorelli, M.G. Chilelli, F. Primi, E.M. Ruggeri |
| 126 |
[GO] |
2021―Dec―10 |
104P Exploring the real-world impact of COVID-19 on first line (1L) treatment and management of EGFR-wild type (EGFR-WT) and ALK-wild type (ALK-WT) metastatic non-small cell lung cancer (mNSCLC) across Europe |
H. Bailey, A. Lee, L. Eccles, Y. Yuan, M. Last, H. Burlison, C. Forshaw, N. Varol |
| 127 |
[GO] |
2021―Dec―10 |
36P Alterations in tumour-promoting cytokines in cancer patients after SARS-CoV-2 infection |
F.H. De Winter, A. Hotterbeekx, M. Huizing, A. Konnova, B. 's Jongers, R.K. Jairam, P. Moons, E. Roelant, D. Le Blon, W. Vanden Berghe, A. Janssens, W. Lybaert, L. Croes, C. Vulsteke, S. Malhotra-Kumar, H. Goossens, Z. Berneman, M. Peeters, P. Van Dam, S. Kumar-Singh |
| 128 |
[GO] |
2021―Dec―10 |
112P Immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in cancer patients receiving immunotherapy agents |
F. Longo Muñoz, A. Cortés Salgado, J.J. Serrano Domingo, J.L. Casado, A. Vallejo, C. Saavedra Serrano, J. Chamorro Pérez, D.I. Rosero Rodríguez, H. Velasco, A. Martin, A. Soria, M.E. Olmedo Garcia, A. Gomez Rueda, Y. Lage, T. Alonso Gordoa, J. Molina Cerrillo, P. Gajate Borau, Í. Martínez del Frade, P. Garrido Lopez, A. Carrato-Mena |
| 129 |
[GO] |
2021―Oct―28 |
Seroconversion rate after vaccination against COVID-19 in cancer patients - a systematic review |
C. Corti, G. Antonarelli, F. Scotté, J.P. Spano, J. Barrière, J.M. Michot, F. André, G. Curigliano |
| 130 |
[GO] |
2021―Oct―22 |
SARS-CoV-2 vaccine uptake, perspectives and adverse reactions following vaccination in patients with cancer undergoing treatment |
J.C. Figueiredo, U. Ihenacho, N.M. Merin, H. Omid;, J. Darrah, J. Gong;, R. Paquette, A.C. Mita, R. Vescio;, I. Mehmi, R. Basho, S.J. Salvy, C.H. Shirazipour, N. Caceres, L.J. Finster, B. Coleman, H.U. Arnow, L. Florindez, K. Sobhani, J.C. Prostko, E.C. Frias, J.L. Stewart, A. Merchant, K.L. Reckamp |
| 131 |
[GO] |
2021―Oct―12 |
21P COVID-19 cancer patients and thromboembolic disease: Survival analysis |
A. Pertejo-Fernandez, S. Martínez-Recio, D. Jiménez-Bou, J. Peña-López, I. Ruiz-Gutiérrez, G. Martín-Montalvo Pérez, A. Rueda-Lara, V. Martínez-Marín |
| 132 |
[GO] |
2021―Oct―12 |
50P Transcriptomic analysis of host immune response for precision drug prediction for SARS-CoV-2 infected patients: An evidence-based approach |
A. Bohra |
| 133 |
[GO] |
2021―Sep―21 |
1600P Suboptimal response to COVID-19 mRNA vaccines in older patients with cancer |
T. Landre, D. Bouharati, M. Ait Amara, C. Taleb |
| 134 |
[GO] |
2021―Sep―21 |
1566MO Resilience of elective cancer surgery systems during COVID-19 lockdowns: International, prospective cohort study of planned surgery for 15 tumour types in 61 countries |
J. Glasbey |
| 135 |
[GO] |
2021―Sep―21 |
1569P A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 infection optionally treated with granulocyte colony-stimulating factor (G-CSF): A comparative analysis |
M. Sereno Moyano, G. Colmenarejo, J. Baena, C. Aguado de la Rosa, X. Mielgo, A. Pertejo, R. Alvarez Alvarez, A. Sánchez, J.L. López, R. Molina, A. Lopez-Alfonso, B. Hernandez, L.E. Chiara Velarde, A.M. Martin, A. López Martin, M. Dorta Suarez, A. Collazo, E. Casado, A. Jimenez Gordo |
| 136 |
[GO] |
2021―Sep―21 |
1580P Impact of COVID-19 infection on breast cancer patients: Experience in Latin-American country ACHOCC-19B study |
A.V. Ospina Serrano, R. Bruges, W. Mantilla, I. Triana, P. Ramos, S. Aruachan, A. Quiroga, I. Munevar, J. Ortiz, N. Llinas, P. Pinilla, H. Vargas, H. Idrobo, A. Russi, R. Manneh, G. Rivas, H. Gonzalez, D. Santa, J. Insuasty, L. Bernal |
| 137 |
[GO] |
2021―Sep―21 |
1579P The risk of severe/critical COVID-19 infection in patients diagnosed with solid malignancies: Two center experience from Armenia |
N. Karapetyan, S. Danielyan, L. Safaryan, L. Harutyunyan, A. Avagyan, G. Tamamyan, T. Arakelyan, J. Arakelyan, S. Bardakhcyan, M. Harutyunyan, A. Sargsyan, M. Mailyan, M. Sargsyan, M. Rushanyan, G. Mkrtchyan, A. Galoyan, D. Zohrabyan |
| 138 |
[GO] |
2021―Sep―21 |
1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20 |
M. Joerger, Y. Metaxas, K. Zaman, O.A. Michielin, N. Mach, D. Betticher, A.M. Schmitt, N. Cantoni, C.B. Caspar, S. Stettler, R. Malval, M. Pless, C. Britschgi, C. Renner, D. Koeberle, J. Schulz, C. Kopp, S. Hayoz, A. Stathis, R. von Moos |
| 139 |
[GO] |
2021―Sep―21 |
41P Testosterone level and severity of COVID-19 infection in ambispective cohorts: The TESTOVID study |
J. Noel, A. Sabouret, E. Auclin, J.B. Arlet, B. Hermann, J.L. Diehl, J.S. Hulot, E. Messas, G. Detriche, D. Lebeaux, S. Baron, A. Blanchard, S. Brabant, B. Djobo, M. Auvray-Kuentz, D. Prie, C. Laouenan, C. Dorival, J.C. Barale, S.M. Oudard |
| 140 |
[GO] |
2021―Sep―21 |
1644P What is the attitude to new vaccines against COVID-19 in cancer patients? |
S. Della Torre, R. Curcio, A. Galeassi, S. DiBella, R. Bollina |
| 141 |
[GO] |
2021―Sep―21 |
1565MO Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry |
D.J. Pinato, M. Patel, M. Lambertini, E. Colomba, F. Pommeret, M. Van Hemelrijick, A. Zambelli, T. Newsom-Davis, R. Salazar, A. Bertuzzi, G. Gaidano, G. Rizzo, G. Patel, E. Felip, A. Prat, J. Aguilar-Company, J. Tabernero, N. Diamantis, A. Gennari, A. Cortellini |
| 142 |
[GO] |
2021―Sep―21 |
1584P Prevalence and risk factors of COVID-19 in cancer patients: A prospective monocentric study |
W. Ben Kridis, S. Khmeri, M. Lajnef, A. Khanfir |
| 143 |
[GO] |
2021―Sep―21 |
1577P Early mortality linked to COVID-19 in cancer patients as compared to historical control in pre-pandemic times |
R. Dienstmann, P. De Marchi, M. Costa e Silva, M. Menezes, H. Cruz, R. Paes, J. Alves da Silva, A.C. Messias, J.A.F. Canedo, A.C. De Melo, T. Reinert, A. Jacome, B.S. Ferreira, C. Mathias, C.H. Barrios, C. Gil Ferreira, B.L. Ferrari |
| 144 |
[GO] |
2021―Sep―21 |
1578P Clinical outcomes of patients with cancer who tested positive for COVID-19 hospitalised in a UK district general hospital |
A. Amjad, N. Hopkins, K.V. Kamposioras, K.H.J. Lim |
| 145 |
[GO] |
2021―Sep―21 |
1599P Vaccination in the COVID-19 era: Attitudes amongst oncology patients |
S. Horan, C. Murphy, R. Keogh, P. Bredin, N. Cooley, B. Ryan, W. Connolly, L. Treanor, A. Lynch, F.E. Barrett, L. French, D. O'Doherty, L. Judge, S. Hamilton, L. Grogan, P. Morris, B. Hennessy, J. Naidoo, O.S. Breathnach, R.T. O'Dwyer |
| 146 |
[GO] |
2021―Sep―21 |
1596P SERONCOVID: Seroconversion in solid-tumor cancer patients (p) after COVID-19 diagnosis |
A. Pous, E. Felip, O. Etxaniz Ulazia, A. Hernández, S. España, M. Romeo Marin, T. Moran, J.G. Molina, G. Fernandez, D.J. Pinato, A.M. Esteve, R. Mesía |
| 147 |
[GO] |
2021―Sep―21 |
LBA60 Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK |
C. Palmieri, L. Turtle, T. Drake, E. Harrison, A. Docherty, B. Greenhalf, P. Openshaw, J.K. Baillie, M.M.G. Semple |
| 148 |
[GO] |
2021―Sep―21 |
1582P Thromboembolic disease in COVID-19 cancer patients: Impact on overall survival and prognostic factors |
A. Pertejo, S. Martinez Recio, D. Jimenez-Bou, J. Peña-Lopez, I. Ruiz-Gutierrez, G. Martín-Montalvo Pérez, A. Rueda-Lara, V. Martinez Marin |
| 149 |
[GO] |
2021―Sep―21 |
1574P Mortality of 1,636 COVID-19 cancer patients (pts) and associated prognostic factors |
P.A. Ascierto, M.H. Secrest, P. Lambert, K. Sarsour, A. Tan, R. Walls, J. Reddy, A. Seetasith, D. Shenison, I. Ngwa, C. Yun, Q. Zhang |
| 150 |
[GO] |
2021―Sep―21 |
1585P COVID-19 cancer patients outcomes in an intensive care setting: A case-control study |
R. Ranchor, N. Pereira, R. Medeiros, R. Romão, M.J. Ramos, A.S. Mendes, I. Peixoto, M. Magalhães, A. Marinho, A. Araújo |
| 151 |
[GO] |
2021―Sep―21 |
1576P COVID-CANCER HUIL - Registry of oncological patients with diagnosis of COVID-19 at Hospital Universitario Infanta Leonor in Madrid (Spain): One year of pandemic |
J. Rogado, B. Obispo, M. Pérez-Pérez, A. Martín-Marino, J.L. García-López, A. Lopez-Alfonso, C. Pangua, G. Serrano-Montero, M.A. Lara |
| 152 |
[GO] |
2021―Sep―21 |
1567MO COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE) |
E. Romano, S. Gennatas, J. Rogado, M. Sekacheva, D. Viñal, R. Lee, A-E. Croitoru, M. Vitorino, S.M. Khallaf, S. Susnjar, S. Widyanti, A. Cardeña, M. Djerouni, M. Rossi, D. Arnold, L. Castelo-Branco, K.J. Harrington, O.A. Michielin, G. Pentheroudakis, S. Peters |
| 153 |
[GO] |
2021―Sep―21 |
1457P The end-of-life experiences for cancer patients with COVID-19 across the two peak pandemic waves |
P. Mcfarlane, J.M. Droney, Y. Kano, S. Wilson, N. Wade, A. Halley |
| 154 |
[GO] |
2021―Sep―21 |
929TiP HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19 |
A. Psyrri, H. Mehanna, P. Economopoulou, S. Porceddu, J. Waldron, E.H. Wen Ong, M.L.K. Chua, N.F. Saba, N. Basté, S. Cavalieri, G. Fountzilas, L.F. Licitra |
| 155 |
[GO] |
2021―Sep―21 |
1588P SARS-CoV-2 antibody seroprevalence and safety of vaccines in cancer patients who recovered from COVID-19 |
M. Patel, E. Felip, R. Sharkey, M. Krengli, J.D. Chester, A. Sita-Lumsden, U. Mukherjee, B. Russell, A. Loizidou, J. Colomba, C. Andrea Cruz, A. Cabirta, I. Ruiz Camps, J. Brunet, A. Sureda, A. Patriarca, C. Tondini, D.J. Pinato, A. Cortellini |
| 156 |
[GO] |
2021―Sep―21 |
1604P Global survey of 104 cancer patient organisations reveals devastating impact of COVID-19 |
F. Reid, F. Cardoso, A. Filicevas, L. Warwick, J. Isaacson, A. Spiegel, E. Baugh, J. Fox, K. Oliver, R. Giles, C.E. MacKay |
| 157 |
[GO] |
2021―Sep―21 |
1623P Phase I clinical trials (CT) forge on despite COVID-19 |
M.J. Lostes Bardaji, E. Aliende, M. Moreno, H.K. Oberoi, I. Braña, O. Saavedra, M. Vieito Villar, G. Alonso, V. Galvao, N. Carballo, M. Beltran, P. Rovira, I. Cidoncha, C. Saura Manich, T. Macarulla Mercade, A. Oaknin, J. Carles Galceran, E. Felip, E. Garralda, S. Perez Pujol |
| 158 |
[GO] |
2021―Sep―21 |
1625P The virtual clinic: An insight into the patient and clinician experience in cancer during COVID-19 |
A. Poovamnilkunnathil, S. Nabhani-Gebara, M. Dalby |
| 159 |
[GO] |
2021―Sep―21 |
1622P The impact of COVID-19 on cancer treatment delivery in Sub-Saharan Africa |
K. Merrell, P. Ochieng, E.B. Osei - Bonsu, E. Seife, K. Kemper, K. Begna, S. Bussman, T. Leavitt, O. Acheamfour, V. Vanderpuye, A. Manirakiza, T. DeWees, E. Addison |
| 160 |
[GO] |
2021―Sep―21 |
1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy |
A. Bayle, K. Ouali, E. Colomba, N. Ibrahimi, S. Foulon, B. Gachot, C. Willekens, A. Stoclin, M. Merad, F. Griscelli, R. Sun, S. Ammari, J-M. Michot, F. André, F. Scotté, B. Besse, J-C. Soria, F. Barlesi, L. Albiges, F. Pommeret |
| 161 |
[GO] |
2021―Sep―21 |
1608P The impact of COVID-19 on the delivery of systemic anti-cancer treatment at Guy’s Cancer Centre |
S. Dolly, B. Russell, C.L. Moss, E. Tsotra, C. Gousis, J. Roca, A. Sita-Lumsden, M. Khan, D. Josephs, K. Zaki, D. Smith, V. Michalarea, R. Kristeleit, D. Enting, L. Flanders, M. Lei, E. Sawyer, J. Spicer, P. Ross, A. Montes, M. Van Hemelrijick |
| 162 |
[GO] |
2021―Sep―21 |
1630P The impact of the COVID-19 outbreak on surgical site infections in elective colorectal cancer surgery: One potential benefit of the pandemic? |
F. Mulita, E. Liolis, L. Tchabashvili, M. Vailas, K. Akinosoglou, S. Assimakopoulos, I. Maroulis, G. Panos |
| 163 |
[GO] |
2021―Sep―21 |
1609P COVID-19 outbreak repercussions on breast cancer diagnoses and access to treatment: Preliminary data from the COVID-DELAY study |
R. Berardi, G. Mentrasti, S. Crocetti, N. La Verde, R. Chiari, M.S. Cona, L. Nicolardi, C. De Filippis, S. Oldani, F. Pecci, F. Venanzi, M.B.L. Rocchi, A. Savini, L. Cantini, M. Pistelli |
| 164 |
[GO] |
2021―Sep―21 |
1627P Management of locally advanced rectal cancer during the COVID-19 outbreak: First results of a shift towards short course neoadjuvant radiotherapy |
B. Castro, F.F. Sousa, A.M. Pires, S. Sarandão, D. Gomes, O. Sousa |
| 165 |
[GO] |
2021―Sep―21 |
1628P Impact of COVID-19 pandemia on the diagnosis of breast cancer in one region of north of Portugal: One year experience |
M. Vilaça, D. Silva, D. Magalhães, F. Estevinho, F. Braga, A. Mesquita, M. Salgado |
| 166 |
[GO] |
2021―Sep―21 |
1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic |
M. Claps, E. Jachetti, R. Ferri, F. Badenchini, E. Verzoni, R. Montone, P. Sepe, V. Guadalupi, A. Ottini, G. Baciarello, R. Valdagni, M.P. Colombo, F. de Braud, G. Procopio |
| 167 |
[GO] |
2021―Sep―21 |
1645P Group psychotherapy in young female cancer patients during COVID-19 pandemic |
M. Abuladze, T. Cholikidze, T. Esakia, S. Tsitsilashvili, N. Koiava, N. Jokhadze, M. Katcharava, N. Otkhozoria, E. Mariamidze, T. Melkadze, M. Maglakelidze, K. Saganelidze |
| 168 |
[GO] |
2021―Sep―21 |
1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic |
G. Gravis Mescam, R. Touzani, J. Pakradouni, P. Bens Soussan, P. Marino |
| 169 |
[GO] |
2021―Sep―21 |
1638P Experience with telemedicine during COVID-19 pandemic |
S. Soriano, P. Ribera, C. Climent, I. Macias Declara, L. Fernandez, L. Vilà, M.A. Segui, C. Pericay |
| 170 |
[GO] |
2021―Sep―21 |
1617P Sustained cancer clinical trial activity during the COVID-19 pandemic |
A. Bayle, C. Baldini, P. Martin Romano, J-M. Michot, S. Champiat, R. Bahleda, A. Gazzah, A. Marabelle, L. Verlingue, A. Geraud, D. Morel, S. Michiels, V. Ribrag, A. Hollebecque, L. Albiges, B. Besse, J-C. Soria, C. Massard, F. Barlesi, S. Postel-Vinay |
| 171 |
[GO] |
2021―Sep―21 |
1618P Worsening of breast and cervical cancer stage at diagnosis due to COVID-19 pandemic |
A.P. Messias, R.R.D.C.C. Bonadio, O.A.N. Moreira, L. Vecchi Leis, B. Zanin Orsi, D. Negrini Batista, L. Testa, M.D.P Estevez Diz |
| 172 |
[GO] |
2021―Sep―21 |
1611P Health-related quality of life, vaccine uptake and immune response among cancer patients undergoing treatment during the COVID-19 pandemic |
J.C. Figueiredo, N. Merin, U. Ihenacho, O. Hamid, A.E. Hendifar, R. Vescio, R. Paquette, R.B. Natale, J. Darrah, R. Basho, H. McArthur, N. Nguyen, N. Punwani, E. Herrera, S. Cheng, S-J. Salvy, G. Datta, R. Figlin, A. Merchant, K.L. Reckamp |
| 173 |
[GO] |
2021―Sep―21 |
CN47 Spanish Oncology Nursing Society efforts during COVID-19 pandemic |
N. Domenech-Climent, J.C. de la Torre-Montero, N. Gil Gomez, M.A. Peñuelas Saiz, I. Magallón Pedrera, R. Cumplido Corbacho, J.M. Gavala Arjona, P. Beorlegui Murillo, J. Serra López, G. Gonzalez Monterrubio |
| 174 |
[GO] |
2021―Sep―21 |
1607P Trends in cancer imaging by indication, care setting, and hospital type during the COVID-19 pandemic and recovery |
O. Zattra, A. Fraga, N. Lu, M.S. Gee, R. Liu, M.H. Lev, J. Brink, S. Saini, M. Lang, M.D. Succi |
| 175 |
[GO] |
2021―Sep―21 |
1575P Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two UK waves of the COVID-19 pandemic at University College London Hospital |
A. Sinclair, I. Earnshaw, A. Chowdhury, G. Patel, N. Chopra, E. Merry, G. Soosaipillai, M. Galazi, S. Benafif, A. Wu, C. Sng, Y.N.S. Wong, D. Ottaviani, H. Shaw, A.J.X. Lee, R. Roylance |
| 176 |
[GO] |
2021―Sep―21 |
1636P Health behavior of cancer patients during COVID-19 pandemic. Focus head neck cancer |
J. Büntzel, O. Micke, A. Büssing, J. Büntzel |
| 177 |
[GO] |
2021―Sep―21 |
1110P COVID-19 pandemic impact on healthcare professionals treating patients with neuroendocrine tumors (NET): An international NET CONNECT survey |
J. Hernando, A. Lamarca, M. Cives, M.E. Caplin, M.E. Pavel |
| 178 |
[GO] |
2021―Sep―21 |
1587P SARS-CoV-2 infection risk and COVID-19 prevalence in cancer patients during the first wave of COVID-19 pandemic in a Northern Italy’s virus epicenter area |
A. Musolino, B. Pellegrino, L. Isella, C. Tommasi, F. Pucci, A. Leonetti, E. Rapacchi, F. Leonardi, S. Bizzoco, P. Affanni, L. Veronesi, P. Sgargi, G. Maglietta, M. Michiara |
| 179 |
[GO] |
2021―Sep―21 |
1634P Communication specifics with cancer patients during the COVID-19 pandemic in Croatia: Can a virtual visit meet the needs of cancer patients? |
R. Kelemenic-Drazin, N. Svilicic, A. Budisavljevic, N. Dedic Plavetic, I. Kardum Fucak, T. Silovski, V. Telesmanic Dobric, M. Nalbani, Z. Curic, Z. Boric-Mikez, T. Ladenhauser, D. Trivanovic, Z. Vojnovic, I. Tomas, S. Plestina |
| 180 |
[GO] |
2021―Sep―21 |
1621P Emotional distress in cancer patients during the first wave of the COVID-19 pandemic in Madrid |
P. Toquero Diez, C. Blanco Fernández, B. Vera Cea, E. Méndez Carrascosa, A. Garrido García, O. Donnay Candil, A.I. Ballesteros García, J.M. Sánchez-Torres, P. Costas Rojo, R. Mondéjar Solís, B. Hernandez, M.D.P. López Martí, R. Colomer Bosch, N. Romero Laorden |
| 181 |
[GO] |
2021―Sep―21 |
1494P Anxiety and depression during the COVID-19 pandemic in newly diagnosed advanced cancer patients |
B. Obispo, R. Hernandez, P. Cruz, A. Fernandez Montes, M. Gil Raga, O.A. Garcia, J. Rogado, E. Asensio-Martinez, N. Piera Molons, V. Pacheco-Barcia, M.H. López de Ceballos, J.M. Cano, L. Ostios Garcia, M. Antoñanzas Basa, D. Lorente, A. Manzano Fernández, S. Hernando Polo, M. Gonzalez Moya, T. Garcia, C. Calderon |
| 182 |
[GO] |
2021―Sep―21 |
390MO Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Q, Canada |
M. Tehfe, D. Charpentier, M-F. Vachon, M. Champagne |
| 183 |
[GO] |
2021―Sep―21 |
1624P Impact of the COVID-19 pandemic in the cancer fast-track programme |
M.T.M. Martinez, S. Simón, J. Montón-Bueno, S. Moragón, B. Ortega Morillo, S. Roselló, J. Navarro, A. Sanmartin, A. Julve, M. Flores, E. Buch, A. Peña, J. Franco, J. Martínez-Jabaloyas, J. Marco, M.J. Forner, A. Cano, B. Bermejo, A. Cervantes, I. Chirivella |
| 184 |
[GO] |
2021―Sep―21 |
1635P Impact of the COVID-19 pandemic on cancer care in Tunisia: Oncologists' perception |
I. Ben Abdallah, H. Rachdi, M. Nesrine, Y. Berrazega, N. Daoud, S. Laabidi, H. Boussen |
| 185 |
[GO] |
2021―Sep―21 |
1615P Impact of the COVID-19 pandemic on diagnosing and treatment referrals of lung cancer patients: A single-centre experience |
U. Janzic, K. Mohorcic, K. Adamic, M. Marc Malovrh |
| 186 |
[GO] |
2021―Sep―21 |
1612P The impact of COVID-19 pandemic on distress level in cancer patients, a cross-sectional multicentric study |
A. Budisavljevic, R. Kelemenic-Drazin, N. Dedic Plavetic, T. Silovski, I. Kardum Fucak |
| 187 |
[GO] |
2021―Sep―21 |
1581P Impact of the COVID-19 pandemic on patients with head and neck cancer assisted in a public cancer center in Brazil |
G.G. Viana Veloso, A. Nogueira Rodrigues |
| 188 |
[GO] |
2021―Sep―21 |
1109P The psychological impact of COVID-19 pandemic on patients with NETs: Between resilience and vulnerability |
E. Lauricella, M. Cives, V. Felici, A. Bracigliano, R. Lippolis, B. Amoruso, E. Pelle, C. Esposto, B. Mandriani, G. Di Lorenzo, O. Clemente, C.G. Porta, S. Tafuto |
| 189 |
[GO] |
2021―Sep―21 |
1572P The impact of COVID-19 pandemic on Spanish genitourinary (GU) cancer patients: SOGUG-COVID-19 study |
M.A. Climent Duran, N. Vidal, S. Pérez, M.J. Méndez-Vidal, G. Anguera, I. Martinez Salas, E. Gallardo, M.A. Cuellar, J.J. Soto, A. Martín, M. Domènech, A. Rodriguez-Vida, E. Almagro Casado, N. Diaz-Mejía, M. Martinez Kareaga, O. Fernandez Calvo, J.C. Villa Guzmán, S. Vazquez, A. Gonzalez del Alba, J. Puente |
| 190 |
[GO] |
2021―Sep―21 |
1492P A longitudinal cohort study on assessing the impact COVID-19 pandemic on the mental health of cancer care providers: Developing world scenario |
A. Thaduri, A. Sehrawat, D.R. Poonia, A. Das, R. Kumar, A. Varghese, R. Kottayasamy Seenivasagam, P.K. Garg, M.K. Gupta, S. Agarwal |
| 191 |
[GO] |
2021―Sep―21 |
1641P Patient preferences towards the application of telemedicine on cancer care during Coronavirus disease 2019 (COVID-19) pandemic. ONCOTELEMED STUDY |
P. Ribera, C. Climent, S. Soriano, I. Macias Declara, L. Fernandez, L. Vilà, M.A. Segui, C. Pericay |
| 192 |
[GO] |
2021―Sep―21 |
1632P At home androgen deprivation therapy for patients with prostate cancer during the COVID-19 pandemic. One center experience |
T. Esakia, T. Melkadze, K. Tsiklauri, E. Mariamidze, S. Tsitsilashvili, N. Otkhozoria, M. Abuladze, N. Jokhadze, N. Balanchivadze |
| 193 |
[GO] |
2021―Sep―21 |
1847P Professional standing of young medical oncologists in Spain during COVID-19 pandemic: A nationwide survey by the Spanish Society of Medical Oncology (SEOM) +MIR Section |
V. Pacheco-Barcia, D.A. Sanchez, B. Obispo, A. Quilez, A. Sesma, P. JimEnez Labaig, D. Paez, T. Quintanar Verduguez, M. Sánchez Cánovas, N. Tarazona, A. Fernandez Montes, E. Felip, A. Rodríguez-Lescure, M.E. Elez Fernandez |
| 194 |
[GO] |
2021―Sep―21 |
1643P Knowledge and attitude of cancer patients towards COVID-19 pandemic: A study from Pakistan |
S. Yaqub, M.A. Khokhar, Z. Jamil, N.B. Butt, A. Zafar, F.R. Lodhi |
| 195 |
[GO] |
2021―Sep―21 |
243P CDK4/6 inhibitors in clinical practice during COVID-19 pandemic: Comparative analysis of the clinical impact of the pandemic for metastatic breast cancer patients during first and second waves in the UK |
M.M. Fouda, V. Kuriakose |
| 196 |
[GO] |
2021―Sep―21 |
1619P Transition to a virtual cancer multidisciplinary team meeting during the COVID-19 pandemic: Experience from a regional Irish Cancer Centre |
C.M. Goggin, N. Myo Oo, M. Hennessy, M. Hamid, P. Lynch, M. O'Connor, A. Horgan, P.M. Calvert, E. Jordan, J. Greene |
| 197 |
[GO] |
2021―Sep―21 |
1605P Being a medical oncologist during the COVID-19 pandemic: Perception, expectations and concerns. OATH study |
O. Tanriverdi |
| 198 |
[GO] |
2021―Sep―21 |
1389P Real world outcomes of locally advanced gastric/GOJ cancers receiving perioperative chemotherapy with FLOT regimen during the COVID-19 pandemic: Results from a regional cancer care centre in the UK |
S. Bose, R. Chowdhary, A. Menon, T. Hafeez, M. Joseph |
| 199 |
[GO] |
2021―Sep―21 |
1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium |
J. Hong, H.T. Borno, O. Harismendy, S. Yousefi, P. Cinar, H.S. Rugo, M-O. Kim, V.S. Koshkin, A. Bailey, R.R. McKay, E.J. Small |
| 200 |
[GO] |
2021―Sep―21 |
1583P COVID-19 related risk in patients enrolled in early-phase clinical trials |
P. D'Amico, P. Trillo, S. Morganti, C. Corti, G. Vivanet, E. Crimini, L. Ascione, P. Tarantino, G. Antonarelli, M. Locatelli, A. Esposito, C. Belli, G. Curigliano |
| 201 |
[GO] |
2021―Sep―21 |
1606P Impact of COVID-19 (SARS-CoV-2, C19) on medical oncologists (MOs) and cancer care: A Canadian Association of Medical Oncologists (CAMO) survey study |
S. Gill, B. Colwell, S. Welch, D. Hao |
| 202 |
[GO] |
2021―Sep―21 |
1560O Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection |
A. Cortellini, E. Roldán, M.C. Carmona Garcia, R. Berardi, A. Sánchez, C. Martinez, A. Parisi, E. Jones, R.M. Bertulli, G. Rizzo, A. Guida, C. Chung, M.D. Bower, M. Betti, B. Vincenzi, O. Mirallas, F. Biello, P. Queirolo, A. Gennari, D.J. Pinato |
| 203 |
[GO] |
2021―Sep―21 |
1586P Assessment of side effects of radiation therapy in patients with COVID-19 treated for early-stage breast cancer |
S. Allali, V. Servois, A. Beddok, A. Fourquet, Y. Kirova |
| 204 |
[GO] |
2021―Sep―21 |
1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity |
R. Obermannova, R. Demlova, I. Selingerova, M. Doubek, D. Okrouhlicova, M. Mlnarikova, K. Pilatova, J. Nevrlka, H. Lejdarova, B. Weinbergerova, Z. Cermakova, D. Valik, J. Mayer, I. Kiss, L. Zdrazilova-Dubska |
| 205 |
[GO] |
2021―Sep―21 |
1595P Acceptance of COVID-19 vaccination among cancer patients in an Irish cancer centre |
W.J. Mullally, C. Flynn, P. Carr, M.J. Kennedy, D. O'Donnell, M. McCarthy, S.P. Alken, K. Cadoo, S. Sukor, M. Lowery, D.J. Gallagher, C. Grant, F. Kelleher, S. Cuffe |
| 206 |
[GO] |
2021―Sep―21 |
1640P Impact of COVID-19 vaccination campaign on psychological status in cancer patients (pts) |
D. Tregnago, S. Pilotto, L. Belluomini, J. Menis, E. Fiorio, M. Pavarana, M. Casali, L. Benini, F. Zacchi, A. Caldart, E. Trevisani, I. Trestini, A. Avancini, D. Cafaro, C. Cadorin, M. Rimondini, L. Del Piccolo, S. Zuliani, M. Milella |
| 207 |
[GO] |
2021―Sep―21 |
1602P COVID-19 vaccination efficacy in cancer patients: An ongoing prospective trial |
T.F. Da Cruz Tomas, I.F. Eiriz, M. Vitorino, R.S. Vicente, A.D. Mendes, M.C. Silva Sousa, S. Braga, T.M. Fiuza, L.A. Gonçalves, C.P. Gonçalves, J. Demengeot |
| 208 |
[GO] |
2021―Sep―21 |
1562MO Effectiveness of COVID-19 vaccination in cancer patients: A nationwide Veterans Affairs study |
J.T-Y. Wu, J. La, W. Branch-Elliman, L.B. Huhmann, S. Han, G. Parmigiani, D. Tuck, M. Brophy, N. Do, A. Lin, N. Munshi, N. Fillmore |
| 209 |
[GO] |
2021―Sep―21 |
1592P Willingness to vaccinate and side effects of COVID-19 vaccination in patients with breast cancer and gynecological malignancies |
M. Forster, R. Würstlein, A. König, S. Beyer, T. Degenhardt, A. Burges, F. Trillsch, S. Mahner, N. Harbeck, A. Chelariu-Raicu |
| 210 |
[GO] |
2021―Sep―21 |
1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers |
S.K. Salgia, J. Malhotra, Z. Zengin, L. Meza, J. Ely, J. Hsu, E. Kelley, A. Chehrazi-Raffle, A. Govindarajan, R. Muddasani, N. Salgia, N. Dizman, N. Chawla, T. Dorff, Y. Lyou, E. Karczewska, J. Trent, R. Salgia, J. Altin, S.K. Pal |
| 211 |
[GO] |
2021―Sep―21 |
1593P COVID-19 vaccine acceptance among Tunisian cancer patients: A cross-sectional study |
E. Ouertani, M. Nesrine, Y. Berrazega, H. Rachdi, M. Bohli, L. Kochbati, H. Boussen |
| 212 |
[GO] |
2021―Sep―21 |
1589P Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options |
M. Zemel, W. Kian, E.H. Kestenbaum, W. Alguayn, D. Levitas, A.A. Sharb, W. Shalata, K. Rouvinov, L. Nesher, A. Yakobson |
| 213 |
[GO] |
2021―Sep―21 |
1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine |
S.J. Thomas, J.L. Perez, S.P. Lockhart, S. Hariharan, N. Kitchin, R. Bailey, K. Liau, E. Lagkadinou, Ö. Türeci, U. Şahin, X. Xu, S.S. Dychter, C. Lu, T. Gentile, W. Gruber |
| 214 |
[GO] |
2021―Sep―21 |
1620P COVID-19 vaccines and cancer: Tailored information for Australia’s diverse populations |
V. Milch, C. Der Vartanian, M. Austen, R. Wang, C. Anderiesz, D. Keefe |
| 215 |
[GO] |
2021―Sep―21 |
CN44 Exploring cancer patients' and survivors’ experiences of cancer care in COVID-19: A longitudinal qualitative study |
M. Dowling, A. Drury, M. Eicher |
| 216 |
[GO] |
2021―Sep―21 |
1616P Drop in early-stage colorectal cancer diagnoses after COVID-19: Preliminary report from the COVID-DELAY study |
G. Mentrasti, V. Cognigni, M. Di Maio, R. Chiari, N. La Verde, C. Zichi, G. Aimar, F. De Vita, S. Marini, M.S. Cona, G. Pinterpe, F. Pecci, A. Migliore, E. Caravita, M.B.L. Rocchi, A. Bittoni, R. Giampieri, L. Cantini, R. Berardi |
| 217 |
[GO] |
2021―Sep―21 |
1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series |
K.H.J. Lim, K. Punie, C. Oing, E. Thorne, K. Murali, K.V. Kamposioras, M. O'Connor, E. Elez, T.M.S. Amaral, P. Garrido Lopez, M. Lambertini, B. Devnani, C.B. Westphalen, G. Morgan, J.B.A.G. Haanen, C. Hardy, S. Banerjee |
| 218 |
[GO] |
2021―Sep―21 |
1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19? |
G.M. Iannantuono, F. Torino, L. Strigari, B. Capotondi, F. Dell'Aria, V. Flaminio, S. Guerriero, G. Parisi, R. Rosenfeld, F. Amodio, B. Creso, L. Filomeno, F. Mastrobattista, A. Meacci, F.E. Palumbo, L. Santurri, S. Sganga, M. Roselli |
| 219 |
[GO] |
2021―Sep―21 |
1568P Clinical and laboratory outcomes of solid cancer patients reinfected with SARS-CoV-2 |
O. Yazıcı, O. Ünsal, N. Özdemir, E. Çubukçu, B. Ocak, A. Üner, A. Özet |
| 220 |
[GO] |
2021―Sep―21 |
1629P SARS-Cov-2 and Cancer Trials Ireland: Impact, resolution, legacy |
S. O'Reilly |
| 221 |
[GO] |
2021―Sep―21 |
1631P Evaluation of the socio-sanitary and emotional impact caused by SARS-CoV-2 in a Spanish cohort of cancer patients after the second pandemic wave |
D. Herrero Rivera, S. López Martín, D. Manzano Moro, B. Esteban Herrera, L. García Sánchez, A.B. Fiorini Talavera, V. de la Cruz Palomero, J.M. Gassent Blesa, M. Soriano Segura, E. Reche Santos, M. Cornide Santos |
| 222 |
[GO] |
2021―Sep―21 |
1591P Immune response after vaccination against SARS-COV-2 in lung cancer (LC) patients (p). Prospective study in the Medical Oncology Department at the Catalan Institute of Oncology-Badalona, Spain: COVID-lung vaccine |
E. Felip, A. Hernandez, L. Notario, M. Cucurull, B. Quirant, M. Saigí, R. Gómez-Castellà, E. Estevez-Macas, S. Coll Fonollosa, P. Torres Bertral, E. Carcereny Costa, M. Domenech, A. Estival, A. López Paradís, A. Pous Badía, M. Romeo Marín, M.T. Moran Bueno |
| 223 |
[GO] |
2021―Sep―21 |
LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors |
S. Oosting, A.A.M. Van der Veldt, C.H. GeurtsvanKessel, R.S.N. Fehrmann, R.S. van Binnendijk, A-M.C. Dingemans, E.F.F. Smit, T.J.N. Hiltermann, G. den Hartog, M. Jalving, T. Westphal, A. Battacharya, M. van der Heiden, C.U. Blank, M.P. Koopmans, C.A. van Els, N.Y. Rots, D. van Baarle, J.B.A.G. Haanen, E.G. de Vries |
| 224 |
[GO] |
2021―Sep―21 |
1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies |
K. Zakurdaeva, O.A. Gavrilina, A.N. Vasileva, S.K. Dubov, V.S. Dubov, V.I. Vorobyev, L.S. Butaev, L.V. Gavrilova, I.Y. Toropova, M. Popova, A. Siniaev, K. Kaplanov, A.A. Petrenko, O.I. Ochirova, E.Y. Chelysheva, Y.V. Sveshnikova, V. Shuvaev, M.E. Grishunina, Y.A. Chabaeva, V.G. Savchenko |
| 225 |
[GO] |
2021―Sep―21 |
1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study |
S.T.C. Shepherd, A. Fendler, L. Au, F. Byrne, K. Wilkinson, M. Wu, A.M. Schmitt, N. Joharatnam-Hogan, B. Shum, L. Del Rosario, K. Edmonds, E. Carlyle, E. Nicholson, M. Howell, C. Swanton, S. Walker, G. Kassiotis, R. Wilkinson, J. Larkin, S. Turajlic |
| 226 |
[GO] |
2021―Sep―21 |
1597P Vaccination against SARS-CoV-2 infection in patients with solid tumors: Experience from Institute for Oncology and Radiology of Serbia (IORS) |
O.I. Djurmez, M. Calamac, M. Dimitrijevic, K. Serovic, I. Minic, J. Oblakovic-Babic, Z. Tomasevic, I. Bozovic-Spasojevic |
| 227 |
[GO] |
2021―Sep―21 |
1626P The perks of SARS-CoV-2 monitoring through serial nasopharyngeal (NP) swabs in an Italian high prevalence area |
L. Bortot, M. Cinausero, D. Iacono, C. Corvaja, G. Pelizzari, G. Targato, D. Zara, V.J. Andreotti, C. Noto, R. Donato, A. Bin, A.M.M. Minisini, G. Fasola |
| 228 |
[GO] |
2021―Sep―21 |
CN45 Effect of SARS-CoV-2 on management of paediatric blood malignancy: A regional cancer centre study |
S. Dhaka, S.K. Beniwal, V. Arora |
| 229 |
[GO] |
2021―Sep―21 |
1603P SARS-CoV-2 seroconversion among oncology healthcare workers in Brazil |
C. Ismael, P.A. Ismael Amaral Silva, C. Marchon da Silva, M.S. Vieira de Melo, B. Ferreira Neto, R. Macario, J. Vieira de Melo, V. Agibert, C. Domenge |
| 230 |
[GO] |
2021―Sep―21 |
1601P SARS-CoV-2 serological response in cancer patients in the Principality of Andorra (COVONCO study) |
C. Royo-Cebrecos, I. Ambatlle, Ï. Robert, J.M. Buldon, D. Vilanova, J. Serrano Pons, E. Baillés, E. Mahia, J. Pujadas olano, F. Cobo, S. Albiol Rodriguez |
| 231 |
[GO] |
2021―Sep―21 |
1598P Acceptance of SARS-CoV-2 vaccination among patients with cancer undergoing immunosuppressive therapy: Portuguese study |
M.J.P. de Sousa, C. Caramujo, N. Julio, J. Correia Magalhães, R. Basto, T. Fraga, I. Ferreira Gomes, I. Pazos, G. Sousa |
| 232 |
[GO] |
2021―Sep―21 |
1646TiP Efficacy of SARS-CoV-2 vaccination in cancer patients during treatment: A prospective observational study (ANTICOV trial) |
R. Passalacqua, M. Ratti, A. Pan, S. Testa, A. Molteni, S. Tonoli, A. Faliva, E. Mainardi, J. Saleri, A. Gobbi, N. Nanni, N. Bacciocchini, G. Donati, R. Marchi, M. Cattaneo, N. Gnocchi, G. Grizzi, M. Brighenti, G. Maglietta, C. Caminiti |
| 233 |
[GO] |
2021―Sep―21 |
1594P SARS-CoV-2 vaccines in cancer patients (pts), real-world data (RWD) from 1069 Belong.life users |
E. Sapir, N. Moisa, A. Litvin, E. Malki, D.A. Vorobiof |
| 234 |
[GO] |
2021―Sep―21 |
1573P First wave mortality data versus full pandemic period from the COVID-CANCER HUIL study |
G. Serrano-Montero, J. Rogado, B. Obispo, C. Pangua, A. Lopez-Alfonso, A. Martín-Marino, M. Pérez-Pérez, J.L. García-López, M.A. Lara |
| 235 |
[GO] |
2021―Sep―21 |
1846P A permanent legacy of the pandemic? Patient and staff views of the introduction of virtual clinics to the Irish oncology service |
R. Kieran, C. Murphy, E. Maher, J. Buchalter, S. Sukor, S.P. Alken |
| 236 |
[GO] |
2021―Sep―20 |
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: Preliminary results from the prospective observational Vax-On study. |
F. Nelli, A. Fabbri, A. Onorato, D. Giannarelli, M.A. Silvestri, J.R. Giron Berrios, A. Virtuoso, E. Marrucci, C. Signorelli, M.G. Chilelli, F. Primi, M. Schirripa, M. Mazzotta, E.M. Ruggeri |
| 237 |
[GO] |
2021―Aug―02 |
Bamlivimab + etesevimab therapy induces SARS-COV-2 immune escape mutations and secondary clinical deterioration in Covid-19 patients with B cell malignancies |
F. POMMERET, J. COLOMBA, C. BIGENWALD, A. LAPARRA, S. BOCKEL, A. BAYLE, J.-M. MICHOT, T. HUESO, L. ALBIGES, P. TIBERGHIEN, S. MAROT, A. JARY, K. LACOMBE, F. GRISCELLI, E. COLOMBA |
| 238 |
[GO] |
2021―Jul―30 |
Reduced SARS-COV-2 infection and death after two doses of COViD-19 vaccines in a series of 1503 cancer patients |
P. Heudel, B. Favier, S. Assaad, P. Zrounba, J.-Y. Blay |
| 239 |
[GO] |
2021―Jul―26 |
PD4-1-3 A result of questionnaire about COVID-19 and chemotherapy, for patients utilizing outpatient chemotherapy center |
Takashi Shibata, Yuki Ishimabushi, Masato Suzuki, Toshiki Uchida, Eiji Sakamoto, Tomohiko Ogasawara, Osamu Yamamuro |
| 240 |
[GO] |
2021―Jul―26 |
SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan |
Toshio Shimizu |
| 241 |
[GO] |
2021―Jul―26 |
SP2-2 COVID-19 impact on the oncology practice in the USA |
Naoto T. Ueno |
| 242 |
[GO] |
2021―Jul―26 |
SP2-1 The impact of COVID-19 on cancer treatment in Japan; actual condition, countermeasure, and task |
Yu Sunakawa |
| 243 |
[GO] |
2021―Jul―26 |
SP2-4 Impact of COVID-19 on clinical practice and research in oncology in Singapore - experience of the National University Cancer Institute |
Ross A. Soo |
| 244 |
[GO] |
2021―Jul―26 |
MO33-5 The impact of chemotherapy for cancer patients with COVID-19 on severity and mortality outcomes: A meta-analysis |
Timotius I. Hariyanto, Andree Kurniawan |
| 245 |
[GO] |
2021―Jul―26 |
MO33-1 Trends in chemotherapy at our hospital and department under the COVID-19 pandemic |
Akihiko Kageyama, Shinichiro Makino, An Ohigashi, Taichi Tamura, Yuka Morita, Shohei Nakamura, Yu Yagi, Yusuke Kanemasa, Tatsu Shimoyama, Yasushi Omuro |
| 246 |
[GO] |
2021―Jul―26 |
MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer |
Lina Inagaki, Takayo Fukuda, Natsue Uehiro, Akemi Kataoka, Hidetomo Morizono, Mami Kurata, Saori Kawai, Jun Masuda, Tomoko Shibayama, Yukinori Ozaki, Mari Hosonaga, Ippei Fukada, Kokoro Kobayashi, Fumikata Hara, Takayuki Kobayashi, Takayuki Ueno, Toshimi Takano, Yoshinori Ito, Shunji Takahashi, Shinji Ohno |
| 247 |
[GO] |
2021―Jul―26 |
MO33-8 A systematic review of chemotherapy for breast cancer patients during the COVID-19 pandemic era |
Devita Widjaja, Daniel Sutanto, Melissa Juliana, Nathania Purnomo, Andree Kurniawan, Bernard Agung Baskoro |
| 248 |
[GO] |
2021―Jul―26 |
MO33-3 Clinical characteristics and outcomes of cancer patients with COVID-19: A study in a single center in the Philippines |
Jessa Gilda P Pandy, Michelle Alcantara, Frances Que, Marie Belle Francia |
| 249 |
[GO] |
2021―Jul―13 |
Severe COVID-19 in patients with hematological cancers presenting with viremia. |
J.M. Michot, T. Hueso, N. Ibrahimi, F. Pommeret, C. Willekens, E. Colomba, S. Francis, A. Bayle, P.H. Cournède, M. Merad, S. Foulon, L. Albiges, B. Gachot, F. Barlesi, J.C. Soria, V. Ribrag, F. Griscelli |
| 250 |
[GO] |
2021―Jul―07 |
Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy |
P. Guisado-Vasco, L. González-Cortijo, G. D’Errico, A. Serrera-Alvarez, G. Sotres-Fernandez, M. García-Coca, J.M. Fernández-Sousa, X.E. Luepke-Estefan, J.A. López-Martín, J.M. Jimeno |
| 251 |
[GO] |
2021―Jul―03 |
SO-1 The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey |
G. Prager, C. Köhne, J. O’Connor, F. Rivera Herrero, D. Santini, H. Wasan, J. Phelip |
| 252 |
[GO] |
2021―Jul―03 |
P-29 Pancreatic cancer during the COVID-19 pandemic: A high-volume Polish centre experience |
M. Durlik, K. Kedzierska-Kapuza, K. Baumgart, M. Nowak-Niezgoda |
| 253 |
[GO] |
2021―Jul―03 |
P-230 Is stereotactic microwave ablation of resectable colorectal liver metastasis an alternative for liver resection in the Covid-19 pandemic? |
T. Chapelle, B. Op de Beeck, B. Bracke, M. Niekel, G. Roeyen, V. Hartman, M. Spinhoven, D. Ysebaert |
| 254 |
[GO] |
2021―Jul―03 |
P-32 SARS-CoV-2 pandemic and delayed presentation of gastrointestinal cancer patients: A retrospective evaluation and the impact on clinical outcome |
B. Ida Bagus |
| 255 |
[GO] |
2021―Jul―03 |
P-293 Implementation of Medic Assistant: Solutions in a digital cloud supporting medical staff in their daily work with oncological patients during the SARS-COV2 pandemic |
M. Kędzierska |
| 256 |
[GO] |
2021―Jul―03 |
P-36 Pancreatic cancer in times of the pandemic |
E. Una Cidon, P. Alonso |
| 257 |
[GO] |
2021―Jul―03 |
P-265 Neoadjuvant radiotherapy for locally advanced rectal cancer during the first wave of COVID19 pandemic: Guy’s cancer cohort experience |
A. Sachdeva, S. Nagpal, M. Grzeda, B. Russell, I. Petkar, A. Qureshi, M. Van Hemelrijck, P. Ross, V. Harris, K. Owczarczyk |
| 258 |
[GO] |
2021―May―08 |
107P CDK4/6i adjustment & tumour response in the COVID-19 era |
Z. Tippu, C. Ryan, C. Harper-Wynne |
| 259 |
[GO] |
2021―May―08 |
154P Impact of COVID-19 on diagnosis and surgical care of patients with breast cancer |
A.K. Lekshmi, D.V. Kumar, P. K, J.P. Dharmarajan, S. Soman, H. Jayamohanan, A. Vinod |
| 260 |
[GO] |
2021―May―08 |
171P Validity and reliability tests of the UNS-CASKQ14 questionnaire about the quality and compliance of breast cancer survivors amid the COVID-19 pandemic |
W. Soewoto, M.D.P. Putra, G.S. Putra |
| 261 |
[GO] |
2021―May―08 |
176P Breast cancer treatment during the first wave of the COVID-19 pandemic at a UK centre |
K. Balachandran, J. Williams, D. Bell, A. Brown, S. Mahmoud, P. Hurhangee, R. Ramakrishnan, S. Cleator, R.C. Coombes, O. Hatcher, F. Rehman, J. Stebbing, L. Kenny |
| 262 |
[GO] |
2021―May―08 |
177P COVID-19 pandemic impact in newly diagnosed breast cancer patients (BCP) at a third level hospital |
M.C. Guillen Sacoto, E. Núñez-Manchón, X. Bargalló, B. Adamo, I. Alonso, M. Mollà, M. Vidal, G. Oses González, X. Caparrós, B. Gonzalez-Farre, N. Chic, O. Martínez-Sáez, B. Ubeda, R. Moreno, I. Cebrecos, J. Fontdevila Font, S. Vidal-Sicart, A. Rodríguez, A. Prat, M. Muñoz |
| 263 |
[GO] |
2021―May―08 |
132P The psychological impact of the COVID-19 pandemic on patients with early breast cancer |
S. Almeida, D. Frasquilho, G. Cotovio, F. Viana, B. Sousa, J. Oliveira, J. Mattson, C. Marzorati, I. Roziner, E. Karademas, E. Kolokotroni, G.S. Stamatakos, K. Mazzocco, R. Pat-Horenczyk, P. Poikonen-Saksela, F. Cardoso, A. Oliveira-Maia |
| 264 |
[GO] |
2021―May―08 |
97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience |
V. Angelis, P. McFarlane, N. Cunningham, S. Gennatas, S.R.D. Johnston, A. Okines, S. McGrath |
| 265 |
[GO] |
2021―Apr―29 |
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients |
R. Palich, M. Veyri, S. Marot, A. Vozy, J. Gligorov, P. Maingon, A.-G. Marcelin, J.-P. Spano |
| 266 |
[GO] |
2021―Apr―28 |
Impaired immunogenicity of BNT162b2 anti SARS-CoV-2 vaccine in patients treated for solid tumors. |
Barrière Jérôme, Chamorey Emmanuel, Adjtoutah Zoubir, Castelnau Olivier, Mahamat Abakar, Marco Sabine, Petit Emmanuel, Leysalle Axel, Raimondi Vincent, Carles Michel |
| 267 |
[GO] |
2021―Mar―29 |
Estrogen and COVID-19: friend or foe? |
A. Di Vincenzo, A. Andrisani, R. Vettor, M. Rossato |
| 268 |
[GO] |
2021―Mar―20 |
Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium |
P. Grivas, A.R. Khaki, T.M. Wise-Draper, B. French, C. Hennessy, C.-Y. Hsu, Y. Shyr, X. Li, T.K. Choueiri, C.A. Painter, S. Peters, B.I. Rini, M.A. Thompson, S. Mishra, D.R. Rivera, J.D. Acoba, M.Z. Abidi, Z. Bakouny, B. Bashir, T. Bekaii-Saab, S. Berg, E.H. Bernicker, M.A. Bilen, P. Bindal, R. Bishnoi, N. Bouganim, D.W. Bowles, A. Cabal, P.F. Caimi, D.D. Chism, J. Crowell, C. Curran, A. Desai, B. Dixon, D.B. Doroshow, E.B. Durbin, A. Elkrief, D. Farmakiotis, A. Fazio, L.A. Fecher, D.B. Flora, C.R. Friese, J. Fu, S.M. Gadgeel, M.D. Galsky, D.M. Gill, M.J. Glover, S. Goyal, P. Grover, S. Gulati, S. Gupta, S. Halabi, T.R. Halfdanarson, B. Halmos, D.J. Hausrath, J.E. Hawley, E. Hsu, M. Huynh-Le, C. Hwang, C. Jani, A. Jayaraj, D.B. Johnson, A. Kasi, H. Khan, V.S. Koshkin, N.M. Kuderer, D.H. Kwon, P.E. Lammers, A. Li, A. Loaiza-Bonilla, C.A. Low, M.B. Lustberg, G.H. Lyman, R.R. McKay, C. McNair, H. Menon, R.A. Mesa, V. Mico, D. Mundt, G. Nagaraj, E.S. Nakasone, J. Nakayama, A. Nizam, N.L. Nock, C. Park, J.M. Patel, K.G. Patel, P. Peddi, N.A. Pennell, A.J. Piper-Vallillo, M. Puc, D. Ravindranathan, M.E. Reeves, D.Y. Reuben, L. Rosenstein, R.P. Rosovsky, S.M. Rubinstein, M. Salazar, A.L. Schmidt, G.K. Schwartz, M.R. Shah, S.A. Shah, C. Shah, J.A. Shaya, S.R.K. Singh, M. Smits, K.E. Stockerl-Goldstein, D.G. Stover, M. Streckfuss, S. Subbiah, L. Tachiki, E. Tadesse, A. Thakkar, M.D. Tucker, A.K. Verma, D.C. Vinh, M. Weiss, J.T. Wu, E. Wulff-Burchfield, Z. Xie, P.P. Yu, T. Zhang, A.Y. Zhou, H. Zhu, L. Zubiri, D.P. Shah, J.L. Warner, G. dL. Lopes |
| 269 |
[GO] |
2021―Mar―18 |
Multidisciplinary tumor boards present technical and financial challenges in the COVID-19 era |
B. Schroeder, E. Cuevas, J.J. Graber |
| 270 |
[GO] |
2021―Feb―24 |
Advances in cancer research dissemination through the pandemic and beyond |
A. Desai, I. Subbiah, V. Subbiah |
| 271 |
[GO] |
2021―Feb―23 |
Predictions of cancer mortality in Europe in 2021: room for hope in the shadow of COVID-19? |
J.M. Martin-Moreno, S. Lessof |
| 272 |
[GO] |
2021―Feb―17 |
Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 |
Claudia Trojaniello, Maria Grazia Vitale, Paolo Antonio Ascierto |
| 273 |
[GO] |
2021―Feb―15 |
The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate |
Marina Chiara Garassino, Malvika Vyas, Elisabeth de Vries, Ravindran Kanesvaran, Rosa Giuliani, Solange Peters |
| 274 |
[GO] |
2021―Feb―09 |
Androgen deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry |
D.H. Kwon, R. Vashisht, H.T. Borno, R.R. Aggarwal, E.J. Small, A.J. Butte, F.W. Huang |
| 275 |
[GO] |
2021―Jan―30 |
Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey |
J. Barrière, J. Gal, B. Hoch, O. Cassuto, A. Leysalle, E. Chamorey, D. Borchiellini |
| 276 |
[GO] |
2021―Jan―29 |
Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy |
M. Montopoli, M. Zorzi, V. Cocetta, T. Prayer-Galetti, S. Guzzinati, E. Bovo, M. Rugge, A. Calcinotto |
| 277 |
[GO] |
2021―Jan―13 |
Multidisciplinary tumor boards as videoconferences - A new challenge in the COVID-19 era |
Markus W. Gross, Heinz Läubli, Dominik Cordier |
| 278 |
[GO] |
2021―Jan―13 |
Commentary: SARS-CoV-2 vaccines and cancer patients |
C. Corti, G. Curigliano |
| 279 |
[GO] |
2020―Nov―22 |
323P Oncology care in the Republic of Kazakhstan during COVID-19 |
D. Kaidarova, Z. Dushimova, O. Shatkoskaya |
| 280 |
[GO] |
2020―Nov―22 |
321P Impact of COVID-19 and lockdown on adherence to treatment schedule among cancer patients |
K. Kalpathi, D. Darshini, A. Aribandi, A.K. Pillai, R. Kumar, A.K. Lingutla, M. Krishnamani, K. Mathi |
| 281 |
[GO] |
2020―Nov―22 |
331P The clock stopped with COVID-19 but continued ticking for cancer patients |
S. Shanmugam Senga |
| 282 |
[GO] |
2020―Nov―22 |
326P Management of diffuse large B cell lymphomas in the COVID-19 era |
D.Z. Ng, H.X. Kang, S.H. Tan, V. Shih, Q. Zhuang, J. Chiang, E.W.Y. Chang, J. Chan, E.Y.L. Poon, N. Somasundaram, K.W. Yeoh, M. Farid, T.P.L. Tang, M. Tao, S.T. Lim, V.S. Yang |
| 283 |
[GO] |
2020―Nov―22 |
327P COVID-19 in patients with oncohematologic diseases in Kazakhstan |
Z. Dushimova, A. Jazyltayeva, B. Nassipov, S. Gabbasova, N. Kemelbekov |
| 284 |
[GO] |
2020―Nov―22 |
325P Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines |
F.V.F. Que, J.G.P. Pandy, M.J.E. Alcantara, M.B. Francia |
| 285 |
[GO] |
2020―Nov―22 |
322P Challenged faced by cancer patients during the COVID-19 pandemic |
M. Krishnamani, R. Kishore, P. Gundlapally, P. M, A.K. Pillai, R. Kumar, A.K. Lingutla, A. Aribandi, K. Mathi |
| 286 |
[GO] |
2020―Nov―22 |
328P Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation |
I.B. Budhi |
| 287 |
[GO] |
2020―Nov―22 |
320P Psychometric interplay of the perception of the real-life impact of COVID-19 pandemic: A cross-sectional survey of patients with newly diagnosed malignancies |
K. Bao, K.M. Cheung, J.C.H. Chow, T.Y.M. Tsui, A. Lau, W. Tsui, K.H. Wong |
| 288 |
[GO] |
2020―Nov―22 |
329P Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria |
A. Mous |
| 289 |
[GO] |
2020―Nov―22 |
318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients |
D.J. Pinato, A. Zambelli, A. Bertuzzi, A. Marrari, N. Saoudi-Gonzalez, O. Mirallas, M. Galazi, D. Generali, S. Grisanti, C. Tondini, A. Prat, J. Tabernero, R. Mesia, R. Salazar, A. Sureda, M. Franchi, L. Chiudinelli, D.G. Illescas, M. Libertini, A. Gennari |
| 290 |
[GO] |
2020―Nov―22 |
319O The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection |
G. Dettorre, N. Diamantis, A. Loizidou, M. Piccart, J. Chester, A. Jackson, V. Tovazzi, V. Fotia, A. Sita-Lumsden, M. Bower, G. Gaidano, E. Felip, D. Ottaviani, C. Sng, L. Rimassa, A. Santoro, J. Aguilar-Company, E. Seguí, S. Dolly, D. Pinato |
| 291 |
[GO] |
2020―Oct―23 |
Reply to the Letter to the Editor “Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients” by N. Bennani and I. M. Bennani-Baiti |
S. Zumerle, M. Montopoli, M. Rugge, A. Alimonti |
| 292 |
[GO] |
2020―Oct―23 |
Genetic and hormonal influence on SARS-CoV-2-infection susceptibility |
M. Montopoli, S. Zumerle, M. Rugge, A. Alimonti |
| 293 |
[GO] |
2020―Oct―21 |
Seroconversion in patients with cancer and oncology healthcare workers infected by SARS-CoV-2 |
Antonio Marra, Daniele Generali, Paola Zagami, Valeria Cervoni, Sara Gandini, Sergio Venturini, Stefania Morganti, Rita Passerini, Roberto Orecchia, Giuseppe Curigliano |
| 294 |
[GO] |
2020―Oct―01 |
COVID-19 associated pancytopenia can be self-limiting and does not necessarily warrant bone marrow biopsy for the purposes of Sars-CoV-2 diagnostics. |
D.S. Hersby, T.H. Do, A.O. Gang, T.H. Nielsen |
| 295 |
[GO] |
2020―Sep―30 |
Androgen Deprivation Therapy in Unlikely to be Effective for Treatment of COVID-19 |
M.E. O’Callaghan, A. Jay, G. Kichenadasse, K.L. Moretti |
| 296 |
[GO] |
2020―Sep―22 |
1672MO "DOMONCOVID PROJECT": A homecare model for cancer patients during COVID-19 |
M. Ratti, G. Grizzi, M. Bonomi, R. Marchi, F. Negri, B. Perrucci, M.O. Giganti, S. Panni, G. Donati, M. Donini, C. Foroni, A. Gobbi, F. Barbin, F. Gerevini, A. Curti, B. Ferrari, J. Saleri, R. Passalacqua |
| 297 |
[GO] |
2020―Sep―22 |
1690P Development of a model to predict hospital admission and severe outcome in cancer patients with COVID-19 |
R. Lee, C. Zhou, R. Shotton, A. Tivey, E. Dickens, P. Huddar, H. McKenzie, H. Boyce, A. Maynard, M.P. Rowe, S. Khan, L. Eastlake, A. Angelakas, M. Baxter, E. Copson, L. Horsley, A. Thomas, C. Wilson, T. Cooksley, A. Armstrong |
| 298 |
[GO] |
2020―Sep―22 |
1695P Risk assessment of admission procedures for cancer patients during the convalescence of COVID-19 |
J. Yu, S. Jiuling, W. Ouyang, L. Gui, J. Zhang, Y. Zhong, H. Qiu, F. Zhou, Y. Wei, C. Xie |
| 299 |
[GO] |
2020―Sep―22 |
1705P SARS-CoV-2 infection among cancer patients receiving antitumor treatment in Italy: A nationwide observational study (CIPOMO ONCO COVID-19) |
M.E. Negru, C. Tondini, A. Pastorino, M. Caccese, A. Cariello, A. Bertolini, G. Buzzatti, S. Cinieri, A. Comandone, F. Grossi, M. Franchini, O. Caffo, O. Garrone, A. Mambrini, F. Leone, C. Chini, F. Agustoni, F. Artioli, L. Blasi, C. Aschele |
| 300 |
[GO] |
2020―Sep―22 |
1722P Longitudinal analysis of biochemical and haematological features of cancer patients with COVID-19 |
A. Tivey, R. Shotton, R. Lee, C. Zhou, K. Banfill, C. Hague, F. Gomes, J.M.J. Weaver, A. Armstrong, T. Cooksley |
| 301 |
[GO] |
2020―Sep―22 |
1726P Expanding the role of medical oncologist in the management of COVID-19 |
L. Ghiglione, E. Auclin, J. Aguilar-Company, N. Epaillard, D. Casadevall Aguilar, L. Masfarré, M. Rodriguez Castells, M. Tagliamento, S. Pilotto, R. Lopez Castro, X. Mielgo Rubio, C. Urbano Centella, J.C. Laguna, D. García-Illescas, M.V. Bluthgen, T. Gorría Puga, J.N. Minatta, C.A. Cruz, A. Prat, L. Mezquita |
| 302 |
[GO] |
2020―Sep―22 |
1776P Analysis of potencial drug interactions in oncologic patients diagnosed with COVID-19 |
X. Fernandez Sala, D. Casadevall Aguilar, L. Masfarré, D. Conde-Estévez |
| 303 |
[GO] |
2020―Sep―22 |
CN27 Value of nurse navigators (NNs) telemonitoring for cancer patients (pts) tested positive for COVID-19 |
D. Mathivon, M. Abbas, A. Barrais, A. Duflot-Boukobza, M. Ferrua, J. Legendre, C. Mendes, M. Merad, E. Minvielle, O. Mir, M. Pons, F. Scotté |
| 304 |
[GO] |
2020―Sep―22 |
CN33 Level and stress factors among nursing professionals of the units with onco-haematological patients diagnosed of COVID-19 |
L. Ahojes |
| 305 |
[GO] |
2020―Sep―22 |
LBA81 Keeping exhausted T-cells in check in COVID-19 |
P. Van Mol, A. Franken, C. Dooms, J. Yserbyt, D. Testelmans, P. Meersseman, G. Hermans, J. Wauters, J. Gunst, K. Nackaerts, J. Vansteenkiste, A. Garg, D. Lambrechts, E. Wauters |
| 306 |
[GO] |
2020―Sep―22 |
1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience |
W. Cui, N. Yousaf, J. Bhosle, A.R. Minchom, M. Ahmed, F. McDonald, I. Locke, R. Lee, M. O'Brien, S. Popat |
| 307 |
[GO] |
2020―Sep―22 |
LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19) |
P. Grivas, J. Warner, Y. Shyr, D. Shah, S.M. Rubinstein, N.M. Kuderer, T.K. Choueiri, D. Rivera, C. Painter, M.A. Thompson, S. Peters, A. Desai, A.R. Khaki, N.A. Pennell, J. Hawley, B. Halmos, M.M. Puc, G.H. Lyman, B.I. Rini, G. Lopes |
| 308 |
[GO] |
2020―Sep―22 |
1718P A French experience on COVID-19 and cancer from an academic general hospital in Paris area |
P.A. Laurain, T. Landrin, A. Benmaziane Teillet, S. Sekkate, D. Billard, P. Lesprit, L-J. Couderc, S. Friard, H. Doubre, P. Beuzeboc, R. Ratta |
| 309 |
[GO] |
2020―Sep―22 |
LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS) |
D. Doroshow, A.L. Schmidt, Z. Bakouny, S. Bhalla, J.A. Steinharter, D. Tremblay, M.M. Awad, A.J. Kessler, G. Bouchard, M. Evans, F. Busser, B.S. Zimmerman, C.R. Curran, T. Jun, R. Haddad, Q. Qin, P.V. Nuzzo, J. Feld, M.D. Galsky, T.K. Choueiri |
| 310 |
[GO] |
2020―Sep―22 |
1578P COVID-19 and hospitalised cancer patients: Now it’s time for patients to talk |
B. Domingo Arrue, R.M. Pastor Marí, A. Tarazona Ortega, L. Fos Saus, C.A. Puchades Olmos, A. Torres Martinez, D. Soriano Polo, G. Suay Montagud, A. Ferrero Micó, F.J. Perea Rojo, N. Gómez Sepúlveda, J.D. Linares Diaz, R.P. Diaz Beveridge, R. Girones Sarrio |
| 311 |
[GO] |
2020―Sep―22 |
1766P COVID-19 and lung cancer: What do we know? |
G. Serrano, J. Rogado, C. Pangua, B. Obispo, A. Martin Marino, M. Perez-Perez, A. Lopez-Alfonso, M.A. Lara |
| 312 |
[GO] |
2020―Sep―22 |
1707P CureCancer digital tool in the routine clinical oncology practice facilitates PROs, communicating with HCPs, treatment adherence and “distancing interventions” during COVID-19 and reduces costs: A feasibility and satisfaction study |
D. Galiti, S. Agelaki, A. Karampeazis, H. Linardou, N. Tsoukalas, E. Arvanitou, E. Georgopoulou, C. Vallilas, K. Syrigos, S. Sgourou, S. Kokkali-Zervos, E. Stamatogianni, A. Boutis, A.N. Christopoulou, L. Kontovinis, A. Mala, G. Rigas, Z. Saridaki-Zoras, O. Nicolatou-Galitis, I. Boukovinas |
| 313 |
[GO] |
2020―Sep―22 |
1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center |
M. Hauchecorne, C. Baldini, S. Foulon, A. Bayle, B. Gachot, F. Pommeret, C. Willekens, F. Griscelli, F. Netzer, C. Balleyguier, S. Ammari, F. André, F. Scotté, B. Besse, J-C. Soria, F. Barlesi, L. Albiges |
| 314 |
[GO] |
2020―Sep―22 |
1756P Cancer patients infected with COVID-19 at La Princesa Hospital: Real-world data study |
P. Toquero Diez, B. Vera Cea, A. Garrido Garcia, E.R. Méndez Carrascosa, D. Bañón Torres, R. Colomer Bosch, N. Romero Laorden, B. Hernández |
| 315 |
[GO] |
2020―Sep―22 |
1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium |
C. Palmieri, L. Turtle, A. Docherty, E. Harrison, T. Drake, B. Greenhalf, P.J. Openshaw, J.K. Baillie, M.G. Semple |
| 316 |
[GO] |
2020―Sep―22 |
LBA79 Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study |
K. de Joode, D. Dumoulin, J. Tol, H. Westgeest, L. Beerepoot, F. Van den Berkmortel, P. Mutsaers, N. van Diemen, O. Visser, H.J. Bloemendal, H. van Laarhoven, L. Hendriks, J.B.A.G. Haanen, E.G.E. de Vries, A-M.C. Dingemans, A. Van der Veldt |
| 317 |
[GO] |
2020―Sep―22 |
1769P Impact of COVID-19 crisis on multidisciplinary tumour board treatment decisions: A cohort analysis from India |
A.K. Jotwani, R.S. Goud, R. Vaghmare, R. Rajan, T. Poovaiah, R. Jain |
| 318 |
[GO] |
2020―Sep―22 |
1686P The impact of the COVID-19 crisis on perceived changes in care and wellbeing of cancer patients and norm participants: Results of the PROFILES registry |
L.V. Van De Poll-franse, B. de Rooij, N. Horevoorts, A.M. May, G. Vink, M. Koopman, H.W.M. van Laarhoven, M. Besselink, S. Oerlemans, O. Husson, S. Beijer, N. Ezendam, N. Raijmakers, B. Wollersheim, M. Hoedjes, S. Siesling, M. van Eenbergen, F. Mols |
| 319 |
[GO] |
2020―Sep―22 |
1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score |
E. Seguí, E. Auclin, D. Casadevall, J. Aguilar-Company, M. Rodriguez, N. Epaillard, M. Tagliamento, S. Pilotto, R. López-Castro, X. Mielgo, C. Urbano, A. Rodríguez, D. García-Illescas, M.V. Bluthgen, L. Masfarré, H. Oliveres, J.N. Minatta, J. Marco-Hernández, A. Prat, L. Mezquita |
| 320 |
[GO] |
2020―Sep―22 |
1675MO Screening of COVID-19 disease based on chest CT and PCR for cancer patients undergoing radiotherapy in a French coronavirus hotspot |
R. Sun, S. Achkar, S. Ammari, S. Bockel, N. Douir, G. Mevel, K. Diop, S. Corbin, F. Hubert, G. Brusadin, M. Merad, A. Laville, K. Ka, A. Bossi, S. Rivera, C. Chargari, E. Deutsch |
| 321 |
[GO] |
2020―Sep―22 |
1734P Do cancer patients really do worse? A study in a UK tertiary hospital within a COVID-19 epicentre |
C.C.T. Sng, A. Wu, Y.N.S. Wong, G.B. Soosaipillai, D. Ottaviani, A.J.X. Lee, M. Galazi, N. Chopra, S. Benafif, H.M. Shaw |
| 322 |
[GO] |
2020―Sep―22 |
1774P The study of physical and mental distress among cancer patients during the COVID-19 epidemic |
N. Naqos, M. Khouchani |
| 323 |
[GO] |
2020―Sep―22 |
1697P Cancer patients’ perceptions, opinions and feelings during the COVID-19 epidemic in the most affected Italian areas: Serial cross-sectional study |
R. Passalacqua, G. Maglietta, M. Ratti, A. Gobbi, M. Bonomi, J. Saleri, G. Grizzi, F. Barbin, L. Bonassi, L. Buffoni, L. Cavanna, F. Gallina, E. Gervasi, C. Iridile, V. Lonati, R. Maddalena, F.A. Meriggi, S. Piloni, F. Campione, C. Caminiti |
| 324 |
[GO] |
2020―Sep―22 |
1763P Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days |
B.Y. Aktas, D.C. Guven, R.F. Degirmenciler, H. Taban, O.H. Aktepe, N. Kertmen, S. Kilickap, O. Dizdar, S. Aksoy, M. Erman, Ş. Yalçın, A. Turker, Z. Arik |
| 325 |
[GO] |
2020―Sep―22 |
1571P Chemotherapy in the COVID-19 era: The patient’s perception |
M. Hennessy, A. Linehan, D. Cowzer, Z. Coyne, O. Fitzpatrick, R. Ní Dhonaill, B.T. Hennessy, L. Grogan, P.G. Morris, O.S. Breathnach |
| 326 |
[GO] |
2020―Sep―22 |
1755P The beginning of the COVID-19 era: The perception of oncological patients (pts) in active treatment at the Brindisi and Mauriziano Hospital Oncology Departments |
D. Loparco, M. Di Maio, L. Orlando, F. Dascanio, C. Caliolo, G. Ignazzi, P. Schiavone, G. Lacidogna, A. Quaranta, D. Marino, G. Del Bene, F. Vignani, P. Fedele, E. Sperti, M. Caloro, S. Terzolo, M. D'Amico, A. Bellezza, R. Comite, S. Cinieri |
| 327 |
[GO] |
2020―Sep―22 |
CN30 Quick WBC using POCT to cancer patients in chemotherapy to avoid hospitalization and risk of COVID-19 exposure in the public |
N.H. Hollaender, S. Johansen, N. Dreyer-Andersen |
| 328 |
[GO] |
2020―Sep―22 |
1771P Do breast cancer patients with COVID-19 have a poor prognosis? Experience in a hospital in Madrid |
B. Obispo, J. Rogado, G. Serrano-Montero, A. Lopez-Alfonso, A. Martin Marino, C. Pangua Mendez, M. Perez-Perez, M.A. Lara |
| 329 |
[GO] |
2020―Sep―22 |
1749P COVID-19 impact and predictive factors for mortality in cancer patients |
E. Sanz Garcia, P. Peinado, I. Moreno, M. Dorta, B. Alvarez, R. Alvarez Gallego, R. Madurga, J. Rodriguez Pascual, L. Ugidos, C. Muñoz, E. Garcia-Rico, A. Cubillo |
| 330 |
[GO] |
2020―Sep―22 |
1770P Clinical and epidemiologic aspects of patients with cancer and COVID-19 in a Brazilian cancer center |
M. Magalhaes, L. Arruda do Rego, C. Vieira de Rebouças, R. de Brito Alves, F. Adami, F.J.S.M. Cruz |
| 331 |
[GO] |
2020―Sep―22 |
1719P Clinical characteristics and 28-day mortality among patients with solid cancers and COVID-19 in a tertiary hospital |
J.C. Tapia, J. Gavira, M. Riudavets, O.J. Ponce, I. Gich, A. Barnadas, M. Majem |
| 332 |
[GO] |
2020―Sep―22 |
1741P Triage procedures for COVID-19 in an Italian cancer centre |
G. Targato, D. Zara, R. Fioraso, L. Bortot, G. Pelizzari, C. Corvaja, L. Palmero, F. Puglisi, C. Andreetta, G.G. Cardellino, A.M. Minisini, G. Fasola |
| 333 |
[GO] |
2020―Sep―22 |
1775P Optimal cancer care in the context of COVID-19 in Australia |
V. Milch, C. Andereisz, D. Hector, S. Turnbull, D. Keefe |
| 334 |
[GO] |
2020―Sep―22 |
1750P Clinical course and outcome of COVID-19 in cancer patients: Early results from the “onCOVID-19” study |
V. Di Noia, M. Squadroni, R. Barile, A. D'Aveni, A. Liguori, F. Brena, S. Dalto, D. Di Cintio, M.G. Sauta, G.L. Ceresoli, P. Salvini, G.D. Beretta |
| 335 |
[GO] |
2020―Sep―22 |
1744P COVID-19 in cancer patients: Risk factors for the development of severe clinical event (SCE) |
J.J. Serrano Domingo, E. Corral de la Fuente, R. Martin Huertas, E.M. Vida Navas, J.J. Soto Castillo, L. Sanz Gomez, J. Torres Jimenez, J. Esteban Villarrubia, I. Orejana Martin, P. Alvarez Ballesteros, J. Pozas Perez, M.V. San Roman Gil, P. Garrido Lopez, A. Carrato Mena |
| 336 |
[GO] |
2020―Sep―22 |
1673MO The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management |
A. Lièvre, A. Turpin, I.L. Ray-Coquard, K. Le Malicot, J. Thariat, G. Ahle, R. Mathieu, V. Sebbagh, D. Debieuvre, A. Canellas, M-L. Garcia-Larnicol, R. Colle, A-C. Hardy-Bessard, L. Mansi, J. Bourhis, P. Gorphe, R. Ursu, A. IDBAIH Ahmed, G. Zalcman, O. Bouche |
| 337 |
[GO] |
2020―Sep―22 |
1746P Impact of PD-1/PD-L1 blockade therapy in COVID-19 infected cancer patients (pts) hospitalization: Results of an Italian study in the province of Modena and Reggio Emilia during SARS-CoV-2 outbreak |
A. Damato, A. Spallanzani, A. Berselli, G. Rovesti, S. Benatti, G. Luppi, C. Pinto |
| 338 |
[GO] |
2020―Sep―22 |
1713P Active smoking and severity of COVID-19 infection in cancer patients |
G.D.H. Marta, E. Auclin, N. Saoudi Gonzalez, D. Casadevall Aguilar, M. Rodriguez Castells, N. Epaillard, M. Tagliamento, S. Pilotto, R. López-Castro, X. Mielgo Rubio, C. Urbano Centella, E. Pineda, F.M. Laia, O. Mirallas, M.V. Bluthgen, L. Masfarré, J.N. Minatta, C.A. Cruz, A. Prat, L. Mezquita |
| 339 |
[GO] |
2020―Sep―22 |
1764P Prevalence, severity and evolution of Coronavirus disease 19 (COVID-19) infection in cancer patients from Mediterranean population |
J. Garde Noguera, M.L. Fernandez-Murga, B. Honrubia Peris, J. García Sánchez, N. Piera Molons, M.D.C. Gomez Soler, T. Fenollosa Sanz, P. Llor Rodriguez, V. Carañana Ballerini, E. Cabrera Espinos, A. Albert Balaguer, A. Fernandez Do Nascimento, A. Pellicer Boigues, A. Llombart Cussac |
| 340 |
[GO] |
2020―Sep―22 |
1698P The presence of COVID-19 makes more cancer patients distressed and time perception may distinguish them |
N.V. Conev, M. Petrova, E. Dimitrova, K. Zhelev, Z.I. Zahariev, K. Nikolov, T. Popov, M. Ivanova, N. Evgeniev, I. Shterev Donev |
| 341 |
[GO] |
2020―Sep―22 |
1677MO COVID-19 mortality in hospitalized cancer patients is not significantly affected by chemotherapy or other anti-cancer treatments |
L. Lee, T. Starkey, J-B. Cazier, R. Kerr, G. Middleton |
| 342 |
[GO] |
2020―Sep―22 |
1704P COVID-19 mortality in patients receiving anti-cancer therapy in a UK national cancer centre |
A. Wu, C.C.T. Sng, S. Benafif, N. Chopra, M. Galazi, A.J.X. Lee, D. Ottaviani, G.B. Soosaipillai, Y.N.S. Wong, H.M. Shaw |
| 343 |
[GO] |
2020―Sep―22 |
LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration |
S. Banerjee, K.H.J. Lim, K.V. Kamposioras, K. Murali, C. Oing, K. Punie, M. O'Connor, B. Devnani, M. Lambertini, C. Benedikt Westphalen, P. Garrido Lopez, T.M.S. Amaral, E. Thorne, G. Morgan, J.B.A.G. Haanen, C. Hardy |
| 344 |
[GO] |
2020―Sep―22 |
1685P Is cancer what determines COVID-19 oncological patient’s outcome or are other external factors involved? Experience in a hospital in Madrid, Spain |
J. Rogado, B. Obispo, C. Pangua, G. Serrano-Montero, A. Martin Marino, A. Lopez-Alfonso, M. Perez-Perez, M. Fontan-Vela, M.A. Lara |
| 345 |
[GO] |
2020―Sep―22 |
1691P Evaluation of practice variation for cancer patients care in a French cancer center during the COVID-19 outbreak |
D. Borchiellini, J-M. Hannoun-Levi, J. Gal, M. Gosset, E. Besrest, E. Francois, A. Pilato, J-M. Ferrero, E. Barranger |
| 346 |
[GO] |
2020―Sep―22 |
1710P International multicentric evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits (TV) during the COVID-19 outbreak |
A. Bizot, P-E. Heudel, M. Karimi, C. Levy, L. Vanlemmens, C. Uzan, E. Deluche, D. Genet, M. Saghatchian, S. Giacchetti, J. Grenier, A. Patsouris, V.C. Dieras, J-Y. Pierga, T. Petit, S. Ladoire, W. Jacot, S. Delaloge, M. Lambertini, B. Pistilli |
| 347 |
[GO] |
2020―Sep―22 |
1725P Development and validation of telematic follow-up for cancer patients during the COVID-19 outbreak |
A. Pastorino, M.E. Negru, A. Vigani, F. Vaira, A. Tognoni, A. Ferrari, I. Ricci, M. Rondini, F. Olcese, A. Milano, F. Cozzani, C. Aschele |
| 348 |
[GO] |
2020―Sep―22 |
LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology |
G. Jerusalem, C.E. Onesti, D.G. Generali, N. Harbeck, H. Wildiers, G. Curigliano, M. Campone, V. Tjan-Heijnen, M. Martin, M. Cristofanilli, L. Pusztai, R. Bartsch, M. Peeters, G. Berchem, M. Tagliamento, J. Cortés, T. Ruhstaller, E.M. Ciruelos, S. Rottey, H.S. Rugo |
| 349 |
[GO] |
2020―Sep―22 |
1682P Outcomes of cancer patients undergoing radiotherapy during the COVID-19 outbreak in Wuhan, China |
M.L.K. Chua, C. Xie, X. Wang, J. Yu |
| 350 |
[GO] |
2020―Sep―22 |
1570P The emotional impact of COVID-19 outbreak on cancer out-patients and their caregivers: Impressions from the heart of the Italian pandemic |
M.S. Cona, D. Dalu, S. Ferrario, N. Tosca, A.R. Gambaro, V. Filipazzi, S. Rota, N.M. La Verde |
| 351 |
[GO] |
2020―Sep―22 |
1740P Assessing the impact of COVID-19 outbreak on the attitudes and practice of Italian oncologists towards breast cancer care and related research activities |
F. Poggio, M. Tagliamento, M. Di Maio, V. Martelli, A. De Maria, E. Barisione, M. Grosso, F. Boccardo, P. Pronzato, L. Del Mastro, M. Lambertini |
| 352 |
[GO] |
2020―Sep―22 |
1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey |
M. Tagliamento, F. Spagnolo, F. Poggio, D. Soldato, B. Conte, T. Ruelle, E. Barisione, A. De Maria, L. Del Mastro, M. Di Maio, M. Lambertini |
| 353 |
[GO] |
2020―Sep―22 |
1681P First results of the COCO study: COVID-19 outcomes in patients with cancer |
E. Seguí, M. García de Herreros, E. Auclin, O. Mirallas, D. Casadevall, M. Rodriguez, N. Epaillard, M. Tagliamento, S. Pilotto, R. López-Castro, X. Mielgo, C. Urbano, D. Pesántez, N. Saoudi, M.V. Bluthgen, L. Masfarré, J.N. Minatta, C.A. Cruz, L. Mezquita, A. Prat |
| 354 |
[GO] |
2020―Sep―22 |
LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) |
J. Baena Espinar, V. Torri, J. Whisenant, F.R. Hirsch, J. Rogado, J. de Castro Carpeño, B. Halmos, G.L. Ceresoli, A. Gomez Rueda, M. Tiseo, E. Felip, M. Majem Tarruella, I. Monnet, U. Tapan, H. Wakelee, L-C. Huang, M.C. Garassino, S. Peters, L. Horn, M. Hellmann |
| 355 |
[GO] |
2020―Sep―22 |
1684P Scientia Potentia Est: How the Italian world of oncology changes in the COVID-19 pandemic |
Z. Ballatore, L. Bastianelli, F. Merloni, N. Ranallo, L. Cantini, L. Mariotti, A. Lucarelli, M. Burattini, R. Berardi |
| 356 |
[GO] |
2020―Sep―22 |
1703P UK Coronavirus Cancer Monitoring Project (UKCCMP): A national reporting network for real time data of the COVID-19 pandemic |
A.C. Olsson-Brown, D.J. Hughes, K. Purshouse, L. Lee, V.W. Cheng, A.J.X. Lee, E. Protheroe, A. Smith, H. Curley, R. Arnold, J-B. Cazier, J. D'Costa, C. Palles, N. Campton, C. Varnai, S. Sivakumar, R. Kerr, G. Middleton |
| 357 |
[GO] |
2020―Sep―22 |
1715P Plinabulin (Plin) is a more favorable option for the prevention of chemotherapy induced neutropenia (CIN) than pegfilgrastim (Peg) during the COVID-19 pandemic |
D. Blayney, R. Mohanlal, L. Huang |
| 358 |
[GO] |
2020―Sep―22 |
1737P National approaches to managing cancer care: Responses of countries in the MENA region to COVID-19 pandemic |
Z. Benbrahim, M. Al Asiri, B. Al Bahrani, M.A.M.A. AlNassar, H.O. Al-Shamsi, A. Bounedjar, N. El Saghir, Z. Fahed, S. Khatib, O.M.R. Khorshid, S. Labidi, N. Mellas, L. Mula-Hussain, A. Saleh Hadi Saeed, A. Jazieh |
| 359 |
[GO] |
2020―Sep―22 |
1762P Delivery of systemic anti-cancer therapy during the COVID-19 pandemic |
O. Fitzpatrick, R. Ní Dhonaill, A. Linehan, Z. Coyne, M. Hennessy, M. Clarke, E. McGee, F. Barrett, C. Matassa, D. O'Doherty, T. Doyle, A. Christie, B.T. Hennessy, L. Grogan, P.G. Morris, O.S. Breathnach, D. Cowzer |
| 360 |
[GO] |
2020―Sep―22 |
1765P Developing a risk assessment score for cancer patients during the COVID-19 pandemic |
A. Indini, M. Cattaneo, M. Ghidini, E. Rijavec, C. Bareggi, B. Galassi, D. Gambini, F. Grossi |
| 361 |
[GO] |
2020―Sep―22 |
1773P Mainstreamed genetic testing for French breast and ovarian cancer patients and its utility during the COVID-19 pandemic |
P.R. Benusiglio, C. Korenbaum, J. Ezenfis, S. Geoffron, C. Paul, S. Richard, V. Byrde, E. Guillerm, N. Basset, J-P. Lotz, N. Chabbert-Buffet, J. Gligorov, F. Coulet |
| 362 |
[GO] |
2020―Sep―22 |
CN31 Oncology nurses' experience in German and French-speaking Switzerland during the COVID-19 pandemic |
M. Eicher, M. Bana, C. Darnac, M.N. Hellberg, S. Colomer-Lahiguera |
| 363 |
[GO] |
2020―Sep―22 |
Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond |
K. Joshi, A. Muhith, C. Milner-Watts, M. Obeid, S. Khakoo, J. Bhosle, A.R. Minchom, M. O'Brien |
| 364 |
[GO] |
2020―Sep―22 |
1687P Oncologists knowledge, attitude and practice in COVID-19 pandemic and its negative impact on them: An international study |
A.R. Jazieh, A.K. Coutinho, A. Bensalem, A.A. Alsharm, H. Errihani, L.Y.I. Mula-Hussain, S. Al-Sukhun, C.A. Sampaio-Filho, O.M. Khorshid, R.B. De Guzman, M.O.F. Alkaiyat, H. Jradi |
| 365 |
[GO] |
2020―Sep―22 |
1728P Evaluation of medical practices in oncology in a context of COVID-19 pandemic in France: Point of view of physicians, PRATICOVID study |
C. Helissey, A. Cessot, L. Boudin, E. Romeo, C. Prieux, D. Ghebriou, A. Schernberg, N. Grellier, C. Joly, O. Bauduceau, C. Thibault, E. Mamou, G. Raynal, S. Setey Eiffel, H. Le Floch, D. Ricard, L. Brureau |
| 366 |
[GO] |
2020―Sep―22 |
1768P Caring for cancer patients in the wake of COVID-19 pandemic in Georgia |
M. Abuladze, K. Saganelidze |
| 367 |
[GO] |
2020―Sep―22 |
1758P Practical issues faced by cancer patients during the COVID-19 pandemic in India |
A.K. Jotwani, R. Jain, R.S. Goud, R. Rajan, R. Vaghmare, T. Poovaiah |
| 368 |
[GO] |
2020―Sep―22 |
1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy |
A. Zambelli, V. Fotia, T. Bosetti, G. Negrini, A. di Croce, C. Moro, P.L. Poletti, A.C. Bettini, E. Arnoldi, C. Messina, B. Merelli, A.P. Callegaro, L. Chiudinelli, S. Mosconi, C. Tondini |
| 369 |
[GO] |
2020―Sep―22 |
CN26 Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland: A qualitative study |
S. Colomer-Lahiguera, K. Ribi, C.M. Witt, M. Eicher |
| 370 |
[GO] |
2020―Sep―22 |
1678P_PR The impact of COVID-19 pandemic on cancer care: A global collaborative study |
A.R. Jazieh, H. Akbulut, G. Curigliano, A. Rogado, A.A. Alsharm, E. Razis, L.Y.I. Mula-Hussain, H. Errihani, A. Khattak, R.B. De Guzman, C.C. Mathias, M.O.F. Alkaiyat, H. Jradi, C.D. Rolfo |
| 371 |
[GO] |
2020―Sep―22 |
1572P Psychological impact of the COVID-19 pandemic on health care workers in oncology in Tunisia |
A. Souilhi, A. Gabsi, F. Letaief-Ksontini, N. Chraiet, Y. Yahiaoui, F. Mghirbi, A. Mokrani, K. Meddeb, M. Ayadi, H. Rais, A. Mezlini |
| 372 |
[GO] |
2020―Sep―22 |
LBA69 Impact of the COVID-19 pandemic on management of medical cancer treatments and psychological consequence for the patients |
F. Joly, A. Leconte, J-M. Grellard, J. Lequesne, G. Binarelli, M. Lange, L. Tron, F. Gernier, C. Rieux, M. Fernette, E. Bastien, A. Morel, B. Legrand, D. Richard, A. Faveyrial, R. Travers, L-F. Pépin, O. Rigal, F. Jardin, B. Clarisse |
| 373 |
[GO] |
2020―Sep―22 |
1777P Launching local treatment guidelines for stage IV cancer during COVID-19 pandemic using ESMO MCBS |
R.A.M. Aboelhassan, M.H. Ali, A. Mohamed, A. Mosa |
| 374 |
[GO] |
2020―Sep―22 |
1717P Behavioral practices of cancer patients during COVID-19 pandemic: A Middle East and North Africa Study |
A.R. Jazieh, Z. Benbrahim, S. Al-Sukhun, A.M. Abusanad, M.O. Alorabi, A.R.A.D. El Kinge, E. Tashkandi, M.A.M.A. AlNassar, A. Bensalem, A.A. Alsharm, H. Errihani, A. Bounedjar, C. Mazouzi, M.O.F. Alkaiyat, H. Jradi, N. Abdelhafiz |
| 375 |
[GO] |
2020―Sep―22 |
1709P Cancer patients' perspectives on the real-world impact of COVID-19 pandemic: A multidisciplinary survey |
K.K.H. Bao, K.M. Cheung, J.C.-H. Chow, C.W.L. Leung, W. Tsui, A. Lau, T. Tse, S. Wan, M. Kwok, K.H. Wong |
| 376 |
[GO] |
2020―Sep―22 |
1573P Anxiety and depression in cancer patients during the COVID-19 pandemic: A single-centre study |
F. Letaief-Ksontini, Y. Zenzri, Y. Yahyaoui, A. Gabsi, A. Mokrani, K. Meddeb, H. Rais, M. Ayadi, N. Chraiet, A. Mezlini |
| 377 |
[GO] |
2020―Sep―22 |
1706P Implementing oncology virtual clinics (VC) in response to COVID-19 pandemic: A transformation driven by a crisis |
N. Almutairi, A. Alolayan, M. Alzahrani, A. Algarni, A. Alhadab, A. Hejazi, N. Abdelhafiz, G.E. Gmati, S. Alshehri, M. Alharbi, F. Alhemoudi, A.R. Jazieh |
| 378 |
[GO] |
2020―Sep―22 |
1730P Electronic medical record (EMR)-assisted phone follow-up (PFU) for breast cancer survivors (CS) during COVID-19 pandemic: An Italian single institution experience |
C. Messina, A. Ferro, E.M. Piras, A. Zanutto, O. Caffo, M. Valeria |
| 379 |
[GO] |
2020―Sep―22 |
1724P Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients |
D.C. Guven, B.Y. Aktas, M.S. Aksun, E. Ucgul, T.K. Sahin, H.C. Yildirim, G. Guner, N. Kertmen, O. Dizdar, S. Kilickap, S. Aksoy, Ş. Yalçın, A. Turker, F.M. Uckun, Z. Arik |
| 380 |
[GO] |
2020―Sep―22 |
1727P COVID-19 pandemic: Impact on doctors in training |
A.R. Farooq, S. Iqbal, N. Abdul Aziz, A. Amasayb, T.N. O'Brien, E. Maher, M.Z. Zameer, M. Conroy, N. Peters, D. Collins |
| 381 |
[GO] |
2020―Sep―22 |
1699P COVID-19 pandemic: Patients’ perspective during cancer treatment |
F. Merloni, N. Ranallo, L. Bastianelli, F. Vitarelli, L. Cantini, Z. Ballatore, G. Ricci, I. Fiordoliva, L. Tassone, B. Ferretti, P. Alessandroni, M. Del Prete, S. Chiorrini, M. Safi, L. Stocchi, G. Benedetti, L. Faloppi, R. Stoico, R. Berardi |
| 382 |
[GO] |
2020―Sep―22 |
1747P Chemotherapy prescriptions and emergency medical care utilization by patients in neo/adjuvant breast cancer treatment during COVID-19 pandemic: Patterns in a Brazilian University Hospital |
F.F. Pimentel, J.M.C. Borba, T.C.G.F. Rodrigues, K.P.I. Peruchi, H.H.A. Carrara, J.M. de Andrade, F.J. Candido dos Reis |
| 383 |
[GO] |
2020―Sep―22 |
1742P Outcomes of the reorganisation of a medical oncology department during the COVID-19 pandemic: Real-word experience |
S.A. Duarte, P. Liu, J. Liz Pimenta, K. Ladeira, I. Grilo, E. Ferreira, P.M. Araujo, M. Rocha, P. Gago, D. Azevedo, M.C. Branco, R. Gomes, A. Teira, T. Sarmento, M. Sousa |
| 384 |
[GO] |
2020―Sep―22 |
1757P Training and information during COVID-19 pandemic: The masterpiece in young oncologists |
N. Ranallo, L. Bastianelli, F. Merloni, L. Cantini, G. Ricci, Z. Ballatore, R. Berardi |
| 385 |
[GO] |
2020―Sep―22 |
1720P How do oncological patients perceive the COVID-19 pandemic? Experience from CHU Liège in Belgium |
C.E. Onesti, H. Schroeder, A. Rorive, B. Sautois, M. Lecocq, M. Goffin, E. Gonne, A. Collinge, L. Nicolaers, O. Wera, A. Catot, C. Loly, A. Paulus, A. Sibille, L.E. Lousberg, F. Troisfontaine, J. Collignon, C. Gennigens, P. Freres, G. Jerusalem |
| 386 |
[GO] |
2020―Sep―22 |
1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy |
J-M. Michot, V. Dozio, F-X. Danlos, M. Vasse, J. Rohmere, M. Roumier, F. Pommeret, E. Kishazi, A. Marabelle, C. Escher, K. Kakalacheva-Beeler |
| 387 |
[GO] |
2020―Sep―22 |
1739P Clinical features and prognostic factors on admission of a prospective cohort of COVID-19 positive cancer patients in a third-level hospital in Madrid, Spain |
J. Fuentes Antras, A. Manzano, G. Marquina Ospina, M. PAZ, J. Benitez, J. Tejerina-Peces, C. Aguado, P. Pérez-Segura |
| 388 |
[GO] |
2020―Sep―22 |
1767P Hypercoagulable state, CD4+ T-lymphocytopenia, dysregulated cytotoxicity and monocyte upregulation in COVID-19 positive cancer patients presenting with severe pneumonia |
J. Fuentes Antras, M. Viñuela, K. Guevara-Hoyer, E. de la Fuente, A. Manzano, G. Marquina Ospina, M. PAZ, A. Ocaña, M. Fernández-Arquero, S. Sánchez-Ramón, P. Pérez-Segura |
| 389 |
[GO] |
2020―Sep―22 |
1689P The appropriateness of invasive ventilation in COVID-19 positive cancer patients: The hardest decision for oncologists |
M. Ghidini, A. Indini, E. Rijavec, C. Bareggi, M. Cattaneo, B. Galassi, D. Gambini, F. Grossi |
| 390 |
[GO] |
2020―Sep―22 |
1732P Prognostic indicators for COVID-19 related deaths in patients with cancer |
A. Linehan, D. Cowzer, M. Hennessy, Z. Coyne, O. Fitzpatrick, A. Nolan, L. Judge, N. Cooley, D. O'Doherty, C. Matassa, T. Doyle, B.T. Hennessy, L. Grogan, P.G. Morris, O.S. Breathnach |
| 391 |
[GO] |
2020―Sep―22 |
1702P COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: The COVINT study |
F. Nichetti, M. Bini, K.F. Dotti, A. Ottini, M. Ambrosini, A. Rametta, R. Leporati, L. Ferrari, F.G.M. De Braud |
| 392 |
[GO] |
2020―Sep―22 |
1760P COVID-19 severe pneumonia in cancer patients: Impact and predictive factors |
P. Peinado, E. Sanz Garcia, I. Moreno, M. Dorta, B. Alvarez, R. Alvarez Gallego, R. Madurga, L. Ugidos, J. Rodriguez Pascual, C. Muñoz, E. Garcia-Rico, A. Cubillo |
| 393 |
[GO] |
2020―Sep―22 |
1743P How I treat COVID-19 webinars: A rapid communication platform between patients and physicians |
E. Kassouf, B. Wong, M. Castonguay |
| 394 |
[GO] |
2020―Sep―22 |
1778P Clinical research at the time of COVID-19: A passion or a real job? |
C. Cagnazzo, S. Testoni, R. Cenna, A. Guarrera, M. Monti, S. Stabile, I. Federici, C. Taverniti, S. Pirondi, A. Ferrari, F. Fragioli |
| 395 |
[GO] |
2020―Sep―22 |
1738P COVID-19: An additional burden on caregivers of cancer patients in Tunisia |
K. Harbegue, N. Mejri, H. El Benna, Y. Berrazega, H. Rachdi, S. Labidi, H. Boussen |
| 396 |
[GO] |
2020―Sep―22 |
1759P Cancer care during COVID-19: Data from 157 patient organisations |
R.H. Giles, E. Baugh, F. Cardoso, A. Filicevas, J. Fox, K. Oliver, F. Reid, A. Spiegel, L. Warwick, C. MacKay |
| 397 |
[GO] |
2020―Sep―22 |
1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospital |
D. García-Illescas, N. Saoudi Gonzalez, O. Mirallas, J. Aguilar-Company, I. Ruiz-Camps, A. Garcia-Alvarez, M.J. Lostes Bardaji, A. Valdivia, D.H. Marmolejo Castaneda, M.A. Rezqallah Aron, D.E. López Valbuena, E. Felip, J. Carles, J. Tabernero |
| 398 |
[GO] |
2020―Sep―22 |
1696P Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study |
F. Grossi, M. Cattaneo, E. Rijavec, M. Ghidini, C. Bareggi, B. Galassi, D. Gambini, E. Berti, A. Indini |
| 399 |
[GO] |
2020―Sep―22 |
LBA83 Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: A multi-centre North London experience |
N. Nalinie Joharatnam-Hogan, D. Daniel Hochhauser, K-K. Shiu, H. Rush, V. Crolley, E. Butcher, A. Sharma, A. Muhammad, N. Vasdev, M. Anwar, G. Kantser, A. Saha, F. Raja, J. Bridgewater, K.H. Khan |
| 400 |
[GO] |
2020―Sep―22 |
1753P Coronavirus or cancer: What are oncological patients most afraid of? |
D.S. Sigorski, P. Sobczuk, K. Kuć, M. Osmola, A. Walerzak, T. Ciszewski, S. Kopeć, K. Hryń, P. Rutkowski, R. Stec, L. Bodnar |
| 401 |
[GO] |
2020―Sep―22 |
1674MO ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: Implications for SARS-CoV-2 |
R. Bao, K. Hernandez, L. Huang, J.J. Luke |
| 402 |
[GO] |
2020―Sep―22 |
1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2 |
C. Jay, L. Stanbery, F. Kerneis, J. Nemunaitis, P. Aaron, L. Manning, G. Wallraven, D. Shanahan, Y. Shen, N. Senzer, E. Bognar |
| 403 |
[GO] |
2020―Sep―22 |
CN29 SARS-CoV-2 and the perspectives of people living with cancer: The AIIAO survey on the Italian lockdown |
V. Biagioli, S. Belloni, B. Albanesi, A. Piredda, R. Caruso |
| 404 |
[GO] |
2020―Sep―22 |
LBA73 The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01 |
P. Kvistborg, A. Gangaev, S. Ketelaars, S. Patiweal, A. Dopler, O. Isaeva, K. Hoefakker, S. De Biasi, C. Mussini, G. Guaraldi, M. Girardis, C. Talavera Ormeno, P. Hekking, N. Lardy, M. Toebes, R. Balderas, T.N. Schumacher, H. Ovaa, A. Cossarizza |
| 405 |
[GO] |
2020―Sep―22 |
1723P Organizational challenges and oncological activity volumes during the SARS-CoV-2 epidemic peak in Verona, Italy |
S. Merler, S. Zuliani, I. Zampiva, D. Tregnago, M. Casali, A. Cavaliere, A. Fumagalli, S.T. Riva, A. Rossi, F. Zacchi, E. Zaninotto, A. Auriemma, M. Pavarana, C. Soldà, L. Benini, M. Borghesani, G. Lo Cascio, E. Tacconelli, S. Pilotto, M. Milella |
| 406 |
[GO] |
2020―Sep―22 |
LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study |
M. Bersanelli, D. Giannarelli, E. Verzoni, S. Buti, U. De Giorgi, A. Clemente, M. Filetti, M. Di Napoli, L. Calvetti, P. Ermacora, A.M. Catino, G. Guaitoli, P. Bonomo, F. Mazzoni, A. Veccia, F. Grosso, M. Maruzzo, E. Rossi, F. Grossi, G. Procopio |
| 407 |
[GO] |
2020―Sep―22 |
1671MO Provision of palliative care for patients with cancer and SARS-CoV-2 infection |
G.B. Soosaipillai, A. Sureda, C. Maluquer Artigal, S. Benafif, N. Chopra, N. Harbeck, R. Wuerstlein, R. Mesia Nin, E. Felip, D. Ottaviani, M. Galazi, A.J.X. Lee, R. Salazar, R. Sharkey, R. Reyes, J. Evans, M.C. Carmona Garcia, J. Tabernero, A. Prat, D.J. Pinato |
| 408 |
[GO] |
2020―Sep―22 |
1733P Real-world data: Cancer and SARS-CoV-2 infection |
B. Nunez Garcia, M. Blanco Clemente, A. Morito Aguilar, M. Martinez Cutillas, C. Traseira, Y. Garitaonaindia, R. Aguado Noya, C. Alfaro Autor, G. Visedo, F. franco, V. calvo de juan, M. Provencio Pulla |
| 409 |
[GO] |
2020―Sep―22 |
1683P SARS-CoV-2 infection and lung cancer management in Europe |
A. Agbarya, A. Addeo, A. Charpidou, A. Araújo, K. Cuppens, O.T. Brustugun, M. Rajer, M. Jakopovic, M.V. Marinca, A. Pluzanski |
| 410 |
[GO] |
2020―Sep―22 |
1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU Liège in Belgium |
M. Lecocq, C.E. Onesti, H. Schroeder, A. Rorive, M. Goffin, E. Gonne, B. Sautois, A. Catot, O. Wera, L. Nicolaers, A. Collinge, J. Collignon, P. Freres, M. Polus, B. Duysinx, F. Vaillant, C. Gennigens, N. Marchal, A. Poncin, G. Jerusalem |
| 411 |
[GO] |
2020―Sep―22 |
1679P Determinants of mortality from SARS-CoV-2 infection in European cancer patients |
D.J. Pinato, C. Sng, Y.N.S. Wong, F. Biello, E. Seguí, J. Aguilar-Company, A. Carbo Bague, A. Patriarca, M.D. Bower, G. Rizzo, R. Bruna, C.A. Cruz, F. D'Avanzo, T. Newsom-Davis, M. Mollà, G. Gaidano, J. Brunet, J. Tabernero, A. Prat, A. Gennari |
| 412 |
[GO] |
2020―Sep―22 |
1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer |
K. Ramkumar, C.A. Stewart, C. Gay, R. Cardnell, L. Diao, Q. Wang, L. Shen, Y. Xi, S. Kundu, C. Della Corte, D. Gibbons, J. Wang, J.V. Heymach, L.A. Byers |
| 413 |
[GO] |
2020―Sep―22 |
1711P SARS-CoV-2 infection in prostate cancer patients: Data from a high-incidence area in Italy |
A. Sbrana, F. Paolieri, F. Bloise, A. Nuzzo, S. Manacorda, E. Sammarco, F. Manfredi, C. Mercinelli, G. Gadducci, N. Giannini, A. Antonuzzo, F. Paiar, A. Falcone, F. Pasqualetti, L. Galli |
| 414 |
[GO] |
2020―Sep―22 |
1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models |
C.A. Stewart, C. Gay, K. Ramkumar, K.R. Cargill, R. Cardnell, M. Nilsson, S. Heeke, E.M. Park, S. Kundu, L. Diao, Q. Wang, L. Shen, Y. Xi, C.M. Della Corte, K. Kundu, D.L. Gibbons, J. Wang, J.V. Heymach, L.A. Byers |
| 415 |
[GO] |
2020―Sep―22 |
LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis |
T.M. Wise-Draper, A. Desai, A. Elkrief, B.I. Rini, D.B. Flora, D.W. Bowles, D. Shah, D. Rivera, D.B. Johnson, G. Lopes, P. Grivas, M.A. Thompson, S. Peters, N.M. Kuderer, N.L. Nock, P. Grover, X. Li, S. Gulati, T.K. Choueiri, J. Warner |
| 416 |
[GO] |
2020―Sep―22 |
1708P Online survey on SARS-CoV-2 infections in cancer patients during a nationwide lockdown in France |
N. Hajjaji, S. Lakhdar, E. Kaczmarek, C. Bellier, S. Bécourt, A. Broyelle, E.I. Girard, S. Giscard, E. Lartigau |
| 417 |
[GO] |
2020―Sep―22 |
1680P SARS-CoV-2 infections in outpatients with cancer: Most infected patients are asymptomatic carriers without impact on chemotherapy |
D. Hempel, V. Milani, A. Kleespies, L. Hempel, F. Ebner, D. Zehn, S. Keim |
| 418 |
[GO] |
2020―Sep―22 |
1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models |
K.R. Cargill, C.A. Stewart, C. Gay, K. Ramkumar, R. Cardnell, M. Nilsson, S. Heeke, E.M. Park, L. Diao, Q. Wang, L. Shen, X. Le, Y. Xi, K. Kundu, D. Gibbons, J. Wang, J.V. Heymach, L.A. Byers |
| 419 |
[GO] |
2020―Sep―22 |
1761P Universal screening of SARS-CoV-2 of oncology healthcare workers - a Brazilian experience |
P.A. Ismael Amaral Silva, C. Ismael, C. Marchon da Silva, C. Domenge |
| 420 |
[GO] |
2020―Sep―22 |
LBA78 A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden |
P. Van Mol, A. Franken, C. Dooms, J. Yserbyt, D. Testelmans, P. Meersseman, G. Hermans, J. Wauters, J. Gunst, K. Nackaerts, J. Vansteenkiste, A. Garg, D. Lambrechts, E. Wauters |
| 421 |
[GO] |
2020―Sep―22 |
1751P Lessons from a pandemic: An audit of acute medical oncology admissions during SARS-CoV-2 outbreak |
A. Ni Choinin, M. Allen, L. Milewski, D.G. Power, R.M. Connolly, D. Collins, S. O'Reilly, R. Bambury |
| 422 |
[GO] |
2020―Sep―22 |
1693P Accurate triage may be efficacious in selecting patients who could safely continue anticancer therapy during SARS-CoV-2 pandemic |
C. Gurizzan, R. Pedersini, C. Fornaro, C. Sardini, M. Zamparini, S. Monteverdi, V. Tovazzi, D. Cosentini, A. Dalla Volta, A. Baggi, A. Turla, P. Di Mauro, L. Lorini, M. Laganà, S. Bianchi, S. Intagliata, F. Consoli, E. Conti, P. Bossi, A. Berruti |
| 423 |
[GO] |
2020―Sep―22 |
1701P Oncological patients’ perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic |
D. Tregnago, S. Zuliani, I. Zampiva, M. Casali, A. Cavaliere, A. Fumagalli, S. Merler, S.T. Riva, A. Rossi, F. Zacchi, E. Zaninotto, A. Caldart, S. Casalino, M. Gaule, D. Kadrija, M. Mongillo, M. Rimondini, L. Del Piccolo, M. Milella, S. Pilotto |
| 424 |
[GO] |
2020―Sep―22 |
1731P Molecular diagnostics for cancer patients and high-risk individuals during the SARS-CoV-2 pandemic at the Institute for Oncology and Radiology of Serbia |
M. Cavic, A. Krivokuca, A. Damjanovic-Velickovic, M. Pavlovic, M. Mihajlovic, J. Rakobradovic, I. Boljevic, E. Malisic, M. Tanic, R. Jankovic |
| 425 |
[GO] |
2020―Sep―22 |
1780TiP Ambulatory follow-up care and monitoring of cancer patients during SARS-CoV-2 pandemic by collecting blood samples at home and monitoring systemic therapy using a smartphone application (COREO-trial) |
M. Peeters, C. Vulsteke, M. Rasschaert, J. Ravelingien, P. Van Vooren, G. Vanhoutte, L. De Backer, P.A. van Dam |
| 426 |
[GO] |
2020―Sep―22 |
CN32 University Hospital Ghent Cancer centre nurse-led e-health support in cancer care during the SARS-CoV-2 pandemic: Results of a single centre observation |
J. De Munter, I. Waeytens, V. Kruse |
| 427 |
[GO] |
2020―Sep―22 |
1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria |
A.S. Berghoff, M. Gansterer, A.C. Bathke, W. Trutschnig, P. Hungerländer, J.M. Berger, J. Kreminger, A. Starzer, R. Schmidt, W. Lamm, M. Raderer, A.D. Gottlieb, N.J. Mauser, M. Preusser |
| 428 |
[GO] |
2020―Sep―22 |
1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres |
L. Aguinaga, R. Ursu, J. Legoff, C. Delauguerre, O. Nguyen, S. Harel, B. Royer, M. sebert, M. Jachiet, C. Lebbé, C. Bonnet, P. Brice, P. Fenaux, B. Plaud, T. Aparicio |
| 429 |
[GO] |
2020―Sep―22 |
1772P Impact assessment of SARS-CoV-2 testing on cancer patients undergoing immunosuppressive treatment |
A. Tavares, D. Magalhães, A. Soares, J. Laranjinha, A. Mesquita, F. Duarte, R.C. Abreu, H. Magalhães, F. Braga, C. Sottomayor, M. Salgado |
| 430 |
[GO] |
2020―Sep―22 |
1752P Epidemiological analysis of SARS-CoV-2 virus infection in patients with solid tumors: The experience of Infanta Sofía University Hospital (HUIS) |
C. Gomez Raposo, S. Falagán, C. Andreu-Vázquez, I.J. Thuissard, C. García Fernández, C. Aguayo Zamora, A.M. Jiménez Gordo, M. López Gómez, M. Merino Salvador, C. Sandoval, M. Sereno Moyano, F. Zambrana, S. Roa Franco, C. Martín Domínguez, J. Moreno Rubio, E. Casado |
| 431 |
[GO] |
2020―Sep―22 |
1393P Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy |
G.L. Banna, O. Cantale, A. Friedlaender, A. Addeo |
| 432 |
[GO] |
2020―Sep―22 |
1779P Revolutionizing clinical trial units in the pandemic era |
C. Cagnazzo, V. Franchina, P. Maggiora, S. Stabile, C. Taverniti, A. Guarrera, I. Federici, S. Testoni, M. Monti, S. Cresta, F. Fragioli |
| 433 |
[GO] |
2020―Aug―22 |
The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality |
Joris R. Delanghe, Marc L. De Buyzere, Sander De Bruyne, Wim Van Criekinge, Marijn M. Speeckaert |
| 434 |
[GO] |
2020―Aug―18 |
Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients |
N.N. Bennani, I.M. Bennani-Baiti |
| 435 |
[GO] |
2020―Jul―31 |
Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus |
G. Curigliano, S. Banerjee, A. Cervantes, M. Garassino, P. Garrido, N. Girard, J. Haanen, K. Jordan, F. Lordick, J.P. Machiels, O. Michielin, S. Peters, J. Tabernero, J.Y. Douillard, G. Pentheroudakis |
| 436 |
[GO] |
2020―Jul―23 |
An analysis of cancer patients with asymptomatic infection of SARS-CoV-2 in a cancer center in Wuhan, China |
P. Yin, R. Zeng, Y.R. Duan, Y. Zhang, X.N. Kuang, H.F. Zhang, S.Z. Wei |
| 437 |
[GO] |
2020―Jul―09 |
Does androgen deprivation therapy protect against severe complications from COVID-19? |
Vaibhav G. Patel, Xiaobo Zhong, Bobby Liaw, Douglas Tremblay, Che-Kai Tsao, Matthew D. Galsky, William K. Oh |
| 438 |
[GO] |
2020―Jun―29 |
First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient |
N. Issa, F. Lacassin, F. Camou |
| 439 |
[GO] |
2020―Jun―29 |
Androgen deprivation and SARS-CoV-2 in men with prostate cancer |
M. Koskinen, O. Carpen, V. Honkanen, M.R.J. Seppänen, P.J. Miettinen, J.A. Tuominen, T. Raivio |
| 440 |
[GO] |
2020―Jun―18 |
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 |
Orazio Caffo, Vittorina Zagonel, Cinzia Baldessari, Alfredo Berruti, Roberto Bortolus, Sebastiano Buti, Giovanni Luca Ceresoli, Maddalena Donini, Paola Ermacora, Giuseppe Fornarini, Lucia Fratino, Cristina Masini, Francesco Massari, Alessandra Mosca, Claudia Mucciarini, Giuseppe Procopio, Marcello Tucci, Elena Verri, Paolo Zucali, Consuelo Buttigliero |
| 441 |
[GO] |
2020―Jun―17 |
COVID-19 in patients with lung cancer |
Jia Luo, Hira Rizvi, Isabel R. Preeshagul, Jacklynn V. Egger, David Hoyos, Chaitanya Bandlamudi, Caroline G. McCarthy, Christina J. Falcon, Adam J. Schoenfeld, Kathryn C. Arbour, Jamie E. Chaft, Robert M. Daly, Alexander Drilon, Juliana Eng, Afsheen Iqbal, W. Victoria Lai, Bob T. Li, Piro Lito, Azadeh Namakydoust, Kenneth Ng, Michael Offin, Paul K. Paik, Gregory J. Riely, Charles M. Rudin, Helena A. Yu, Marjorie G. Zauderer, Mark T.A. Donoghue, Marta Łuksza, Benjamin D. Greenbaum, Mark G. Kris, Matthew D. Hellmann |
| 442 |
[GO] |
2020―May―20 |
Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic |
Amit Sud, Michael Jones, John Broggio, Chey Loveday, Bethany Torr, Alice Garrett, David L. Nicol, Shaman Jhanji, Stephen A. Boyce, Firza Gronthoud, Phillip Ward, Jonathan M. Handy, Nadia Yousaf, James Larkin, Yae-Eun Suh, Stephen Scott, Paul D.P. Pharoah, Charles Swanton, Christopher Abbosh, Matthew Williams, Georgios Lyratzopoulos, Richard Houlston, Clare Turnbull |
| 443 |
[GO] |
2020―May―13 |
Personalized Cancer Supportive Care in COVID-19 Era |
G.H. Lyman, N. Kuderer |
| 444 |
[GO] |
2020―May―06 |
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532) |
M. Montopoli, S. Zumerle, R. Vettor, M. Rugge, M. Zorzi, C.V. Catapano, G.M. Carbone, A. Cavalli, F. Pagano, E. Ragazzi, T. Prayer-Galetti, A. Alimonti |
| 445 |
[GO] |
2020―May―01 |
Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19 |
M.L. Solodky, C. Galvez, B. Russias, P. Detourbet, V. N’Guyen-Bonin, A.-L. Herr, P. Zrounba, J.-Y. Blay |
| 446 |
[GO] |
2020―Apr―21 |
Management of hepatocellular carcinoma in the time of COVID-19 |
Massimo Iavarone, Angelo Sangiovanni, Gianpaolo Carrafiello, Giorgio Rossi, Pietro Lampertico |
| 447 |
[GO] |
2020―Apr―21 |
Do Patients with Cancer Have a Poorer Prognosis of COVID-19? An Experience in New York City. |
Hirotaka Miyashita, Takahisa Mikami, Nitin Chopra, Takayuki Yamada, Svetlana Chernyavsky, Dahlia Rizk, Christina Cruz |
| 448 |
[GO] |
2020―Apr―09 |
Testing for COVID-19 in lung cancer patients |
Antonio Passaro, Solange Peters, Tony S.K. Mok, Ilaria Attili, Tetsuya Mitsudomi, Filippo de Marinis |
| 449 |
[GO] |
2020―Apr―09 |
French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak |
N. Penel, S. Bonvalot, V. Minard, D. Orbach, F. Gouin, N. Corradini, M. Brahmi, P. Marec-Bérard, S. Briand, N. Gaspar, C. Llacer, S. Carrère, A. Dufresne, A. Le Cesne, J.Y. Blay |
| 450 |
[GO] |
2020―Apr―02 |
Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report |
Jean-Marie Michot, Laurence Albiges, Nathalie Chaput, Veronique Saada, Fanny Pommeret, Franck Griscelli, Corinne Balleyguier, Benjamin Besse, Aurélien Marabelle, Florence Netzer, Mansouria Merad, Caroline Robert, Fabrice Barlesi, Bertrand Gachot, Annabelle Stoclin |
| 451 |
[GO] |
2020―Mar―31 |
COVID-19 Infection in Cancer Patients: Early Observations and Unanswered Questions |
William K. Oh |
| 452 |
[GO] |
2020―Mar―31 |
A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore |
Natalie Ngoi, Joline Lim, Samuel Ow, Wei Ying Jen, Matilda Lee, Winnie Teo, Jingshan Ho, Raghav Sundar, Moon Ley Tung, Yee Mei Lee, Ednajoy Ngo, Siew Woon Lim, Jason Ong, Frances Lim, Glenn Bonney, Balamurugan Vellayappan, Francis Ho, Jeremy Tey, Noreen Chan, Sanjay de Mel, Michelle Poon, Shir Ying Lee, Liang Piu Koh, Te Chih Liu, Lip Kun Tan, Alvin Wong, Andrea Wong, Siew Eng Lim, Allen Yeoh, John EL. Wong, David Tan, Boon Cher Goh, Wee Joo Chng, Ross Soo, Cheng Ean Chee, Yen Lin Chee, Soo Chin Lee, Anand D. Jeyasekharan |
| 453 |
[GO] |
2020―Mar―26 |
Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China |
L. Zhang, F. Zhu, L. Xie, C. Wang, J. Wang, R. Chen, P. Jia, H.Q. Guan, L. Peng, Y. Chen, P. Peng, P. Zhang, Q. Chu, Q. Shen, Y. Wang, S.Y. Xu, J.P. Zhao, M. Zhou |
| 454 |
[GO] |
2020―Mar―19 |
Managing COVID-19 in the oncology clinic and avoiding the distraction effect |
Cortiula Francesco, Aleksandra Pettke, Bartoletti Michele, Puglisi Fabio, Thomas Helleday |
| 455 |
[GO] |
2020―Mar―09 |
Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19 |
Jinrong Qu, Rui Yang, Liucun Song, Ihab R. Kamel |
|
